<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="02708e1b-b097-49f8-a043-62501008bbd8"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use ALPRAZOLAM TABLETS safely and effectively. See full prescribing information for ALPRAZOLAM TABLETS. <br/>ALPRAZOLAM tablets, for oral use, CIV <br/>Initial U.S. Approval: 1981</title>
   <effectiveTime value="20250402"/>
   <setId root="e06b3bdd-ae21-4503-861e-11412bb7e7ea"/>
   <versionNumber value="14"/>
   <author>
      <assignedEntity>
         <representedOrganization>
            <id extension="830016429" root="1.3.6.1.4.1.519.1"/>
            <name>A-S Medication Solutions</name>
            <assignedEntity>
               <assignedOrganization>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="830016429" root="1.3.6.1.4.1.519.1"/>
                        <name>A-S Medication Solutions</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C73607" displayName="RELABEL" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="50090-5258" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C73606" displayName="REPACK" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="50090-5258" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section ID="DLDE">
               <id root="7cb93149-8ef2-4d52-b475-627e7a2ebed6"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL PRODUCT DATA ELEMENTS SECTION"/>
               <effectiveTime value="20210412"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="50090-5258" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Alprazolam</name>
                        <formCode code="C42998" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Alprazolam</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <asEquivalentEntity classCode="EQUIV">
                           <code code="C64637" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <definingMaterialKind>
                              <code code="51991-706" codeSystem="2.16.840.1.113883.6.69"/>
                           </definingMaterialKind>
                        </asEquivalentEntity>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator value="1" unit="mg"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="YU55MQ3IZY" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ALPRAZOLAM</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="YU55MQ3IZY" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>ALPRAZOLAM</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EWQ57Q8I5X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>LACTOSE MONOHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MICROCRYSTALLINE CELLULOSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="AG9B65PV6B" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM STARCH GLYCOLATE TYPE A CORN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="RFW2ET671P" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYDROXYPROPYL CELLULOSE (1600000 WAMW)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="368GB5141J" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM LAURYL SULFATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="L06K8R7DQK" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FD&amp;C BLUE NO. 2</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="30" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="50090-5258-1" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20201015"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="60" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="50090-5258-2" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20201015"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="100" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="50090-5258-3" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20201015"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="90" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="50090-5258-0" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20201015"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA207507" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="completed"/>
                           <effectiveTime>
                              <low value="20180709"/>
                              <high value="20251031"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <policy classCode="DEADrugSchedule">
                           <code code="C48677" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CIV"/>
                        </policy>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48333" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLUE" xsi:type="CE">
                              <originalText>light blue to blue</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="2" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48345" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="OVAL" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="9" unit="mm" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">B706</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="BOX">
               <id root="2ba2c09d-e264-4089-b99f-254477caf50d"/>
               <code code="34066-1" codeSystem="2.16.840.1.113883.6.1" displayName="BOXED WARNING SECTION"/>
               <title>
                  <content styleCode="emphasis">WARNING: RISKS FROM CONCOMITANT USE WITH OPIOIDS; ABUSE, MISUSE, AND ADDICTION; and DEPENDENCE AND WITHDRAWAL REACTIONS</content>
               </title>
               <text>
                  <list listType="unordered" styleCode="disc">
                     <item>
                        <content styleCode="bold">Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of these drugs for patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Follow patients for signs and symptoms of respiratory depression and sedation <content styleCode="italics">[see <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>, <linkHtml href="#S7.1">Drug Interactions (7.1)</linkHtml>]</content>.</content>
                     </item>
                     <item>
                        <content styleCode="xmChange">
                           <content styleCode="bold">The use of benzodiazepines, including alprazolam tablets, exposes users to risks of abuse, misuse, and addiction, which can lead to overdose or death. Abuse and misuse of benzodiazepines commonly involve concomitant use of other medications, alcohol, and/or illicit substances, which is associated with an increased frequency of serious adverse outcomes. Before prescribing alprazolam tablets and throughout treatment, assess each patient's risk for abuse, misuse, and addiction <content styleCode="italics">[see <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>]</content>.</content>
                        </content>
                     </item>
                     <item>
                        <content styleCode="xmChange">
                           <content styleCode="bold">The continued use of benzodiazepines, including alprazolam tablets, may lead to clinically significant physical dependence. The risks of dependence and withdrawal increase with longer treatment duration and higher daily dose. Abrupt discontinuation or rapid dosage reduction of alprazolam tablets after continued use may precipitate acute withdrawal reactions, which can be life-threatening. To reduce the risk of withdrawal reactions, use a gradual taper to discontinue alprazolam tablets or reduce the dosage <content styleCode="italics">[see <linkHtml href="#S2.2">Dosage and Administration (2.2)</linkHtml>, <linkHtml href="#S5.3">Warnings and Precautions (5.3)</linkHtml>]</content>.</content>
                        </content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20210412"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>WARNING: RISKS FROM CONCOMITANT USE WITH OPIOIDS; ABUSE, MISUSE, AND ADDICTION; and DEPENDENCE AND WITHDRAWAL REACTIONS</paragraph>
                        <paragraph>
                           <content styleCode="italics">See full prescribing information for complete boxed warning.</content>
                        </paragraph>
                        <list listType="unordered" styleCode="disc">
                           <item>
                              <content styleCode="bold">Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing for use in patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Follow patients for signs and symptoms of respiratory depression and sedation. (<linkHtml href="#S5.1">5.1</linkHtml>, <linkHtml href="#S7.1">7.1</linkHtml>)</content>
                           </item>
                           <item>
                              <content styleCode="bold">The use of benzodiazepines, including alprazolam tablets, exposes users to risks of abuse, misuse, and addiction, which can lead to overdose or death. Before prescribing alprazolam tablets and throughout treatment, assess each patient's risk for abuse, misuse, and addiction. (<linkHtml href="#S5.2">5.2</linkHtml>)</content>
                           </item>
                           <item>
                              <content styleCode="bold">Abrupt discontinuation or rapid dosage reduction of alprazolam tablets after continued use may precipitate acute withdrawal reactions, which can be life-threatening. To reduce the risk of withdrawal reactions, use a gradual taper to discontinue alprazolam tablets or reduce the dosage. (<linkHtml href="#S2.2">2.2</linkHtml>, <linkHtml href="#S5.3">5.3</linkHtml>)</content>
                           </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section>
               <id root="82815424-5022-4b66-a802-1c6094bea26e"/>
               <code code="43683-2" codeSystem="2.16.840.1.113883.6.1" displayName="RECENT MAJOR CHANGES SECTION"/>
               <effectiveTime value="20210412"/>
               <excerpt>
                  <highlight>
                     <text>
                        <table styleCode="Noautorules" width="100%">
                           <col width="80%" align="left" valign="top"/>
                           <col width="20%" align="right" valign="bottom"/>
                           <tbody>
                              <tr>
                                 <td>
                                    <linkHtml href="#BOX">Boxed Warning</linkHtml>
                                 </td>
                                 <td>2/2021</td>
                              </tr>
                              <tr>
                                 <td>Dosage and Administration (<linkHtml href="#S2.3">2.3</linkHtml>)</td>
                                 <td>2/2021</td>
                              </tr>
                              <tr>
                                 <td>Warnings and Precautions (<linkHtml href="#S5.2">5.2</linkHtml>, <linkHtml href="#S5.3">5.3</linkHtml>)</td>
                                 <td>2/2021</td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S1">
               <id root="2a59d158-ae0b-4ddd-9f54-515cd056ae0d"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <text>
                  <paragraph>Alprazolam tablets are indicated for the:</paragraph>
                  <list listType="unordered" styleCode="disc">
                     <item>acute treatment of generalized anxiety disorder (GAD) in adults.</item>
                     <item>treatment of panic disorder (PD), with or without agoraphobia in adults.</item>
                  </list>
               </text>
               <effectiveTime value="20210412"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Alprazolam Tablets are a benzodiazepine indicated for the:</paragraph>
                        <list listType="unordered" styleCode="disc">
                           <item>Acute treatment of generalized anxiety disorder in adults. (<linkHtml href="#S1">1</linkHtml>)</item>
                           <item>Treatment of panic disorder with or without agoraphobia in adults. (<linkHtml href="#S1">1</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S2">
               <id root="8796adec-627f-4829-9fb2-8246324cf19a"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <effectiveTime value="20210414"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="disc">
                           <item>
                              <content styleCode="underline">Generalized Anxiety Disorder:</content> (<linkHtml href="#S2.1">2.1</linkHtml>)<list listType="unordered" styleCode="circle">
                                 <item>Recommended starting oral dosage is 0.25 mg to 0.5 mg three times daily.</item>
                                 <item>Dosage may be increased, at intervals of every 3 to 4 days, to a maximum recommended daily dose of 4 mg, given in divided doses.</item>
                                 <item>Use the lowest possible effective dose and frequently assess the need for continued treatment.</item>
                              </list>
                           </item>
                           <item>
                              <content styleCode="underline">Panic Disorder:</content> Recommended starting oral dosage is 0.5 mg three times daily. The dosage may be increased at intervals of every 3 to 4 days in increments of no more than 1 mg per day. (<linkHtml href="#S2.2">2.2</linkHtml>)</item>
                           <item>When tapering, decrease dosage by no more than 0.5 mg every 3 days. Some patients may require an even slower dosage reduction. (<linkHtml href="#S2.3">2.3</linkHtml>, <linkHtml href="#S5.2">5.2</linkHtml>)</item>
                           <item>See the Full Prescribing Information for the recommended dosage in geriatric patients, patients with hepatic impairment, and with use with ritonavir. (<linkHtml href="#S2.4">2.4</linkHtml>, <linkHtml href="#S2.5">2.5</linkHtml>, <linkHtml href="#S2.6">2.6</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S2.1">
                     <id root="a751343c-aae3-4fd6-a9eb-74e6df29c297"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.1 Dosage in Generalized Anxiety Disorder</title>
                     <text>
                        <paragraph>The recommended starting oral dosage of alprazolam tablets for the acute treatment of patients with GAD is 0.25 mg to 0.5 mg administered three times daily. Depending upon the response, the dosage may be adjusted at intervals of every 3 to 4 days. The maximum recommended dosage is 4 mg daily (in divided doses).</paragraph>
                        <paragraph>Use the lowest possible effective dose and frequently assess the need for continued treatment <content styleCode="italics">[see <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20210412"/>
                  </section>
               </component>
               <component>
                  <section ID="S2.2">
                     <id root="07e258ee-ca4f-460d-bafb-912d76c6d147"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.2 Dosage in Panic Disorder</title>
                     <text>
                        <paragraph>The recommended starting oral dosage of alprazolam tablets for the treatment of PD is 0.5 mg three times daily. Depending on the response, the dosage may be increased at intervals of every 3 to 4 days in increments of no more than 1 mg per day.</paragraph>
                        <paragraph>Controlled trials of alprazolam tablets in the treatment of panic disorder included dosages in the range of 1 mg to 10 mg daily. The mean dosage was approximately 5 mg to 6 mg daily. Occasional patients required as much as 10 mg per day.</paragraph>
                        <paragraph>For patients receiving doses greater than 4 mg per day, periodic reassessment and consideration of dosage reduction is advised. In a controlled postmarketing dose-response study, patients treated with doses of alprazolam tablets greater than 4 mg per day for 3 months were able to taper to 50% of their total maintenance dose without apparent loss of clinical benefit.</paragraph>
                        <paragraph>The necessary duration of treatment for PD in patients responding to alprazolam tablets is unknown. After a period of extended freedom from panic attacks, a carefully supervised tapered discontinuation may be attempted, but there is evidence that this may often be difficult to accomplish without recurrence of symptoms and/or the manifestation of withdrawal phenomena <content styleCode="italics">[see <linkHtml href="#S2.3">Dosage and Administration (2.3)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20210414"/>
                  </section>
               </component>
               <component>
                  <section ID="S2.3">
                     <id root="fdd84f99-043f-4d03-97ab-83674eea5d6c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.3 Discontinuation or Dosage Reduction of Alprazolam Tablets</title>
                     <text>
                        <paragraph>
                           <content styleCode="xmChange">To reduce the risk of withdrawal reactions, use a gradual taper to discontinue alprazolam tablets or reduce the dosage. If a patient develops withdrawal reactions, consider pausing the taper or increasing the dosage to the previous tapered dosage level. Subsequently decrease the dosage more slowly <content styleCode="italics">[see <linkHtml href="#S5.3">Warnings and Precautions (5.3)</linkHtml>, <linkHtml href="#S9.3">Drug Abuse and Dependence (9.3)</linkHtml>]</content>.</content>
                        </paragraph>
                        <paragraph>Reduce the dosage by no more than 0.5 mg every 3 days. Some patients may benefit from an even more gradual discontinuation. Some patients may prove resistant to all discontinuation regimens.</paragraph>
                        <paragraph>In a controlled postmarketing discontinuation study of panic disorder patients which compared the recommended taper schedule with a slower taper schedule, no difference was observed between the groups in the proportion of patients who tapered to zero dose; however, the slower schedule was associated with a reduction in symptoms associated with a withdrawal syndrome.</paragraph>
                     </text>
                     <effectiveTime value="20210412"/>
                  </section>
               </component>
               <component>
                  <section ID="S2.4">
                     <id root="5c45c59e-a023-4cf4-bfeb-b75f1fb971d3"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.4 Dosage Recommendations in Geriatric Patients</title>
                     <text>
                        <paragraph>In geriatric patients, the recommended starting oral dosage of alprazolam tablets is 0.25 mg, given 2 or 3 times daily. This may be gradually increased if needed and tolerated. Geriatric patients may be especially sensitive to the effects of benzodiazepines. If adverse reactions occur at the recommended starting dosage, the dosage may be reduced <content styleCode="italics">[see <linkHtml href="#S8.5">Use in Specific Populations (8.5)</linkHtml>, <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20210412"/>
                  </section>
               </component>
               <component>
                  <section ID="S2.5">
                     <id root="a2387345-3b9f-4cbc-b397-20826474319b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.5 Dosage Recommendations in Patients with Hepatic Impairment</title>
                     <text>
                        <paragraph>In patients with hepatic impairment, the recommended starting oral dosage of alprazolam tablets is 0.25 mg, given 2 or 3 times daily. This may be gradually increased if needed and tolerated. If adverse reactions occur at the recommended starting dose, the dosage may be reduced <content styleCode="italics">[see <linkHtml href="#S8.6">Use in Specific Populations (8.6)</linkHtml>, <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20210412"/>
                  </section>
               </component>
               <component>
                  <section ID="S2.6">
                     <id root="eef3fc73-aa20-4608-9ee0-b7a453bbf276"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.6 Dosage Modifications for Drug Interactions</title>
                     <text>
                        <paragraph>Alprazolam tablets should be reduced to half of the recommended dosage when a patient is started on ritonavir and alprazolam together, or when ritonavir is administered to a patient treated with alprazolam. Increase the alprazolam tablets dosage to the target dose after 10 to 14 days of dosing ritonavir and alprazolam together. It is not necessary to reduce alprazolam tablets dose in patients who have been taking ritonavir for more than 10 to 14 days.</paragraph>
                        <paragraph>Alprazolam tablets are contraindicated with concomitant use of all strong CYP3A inhibitors, except ritonavir <content styleCode="italics">[see <linkHtml href="#S4">Contraindications (4)</linkHtml>, <linkHtml href="#S5.5">Warnings and Precautions (5.5)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20210412"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S3">
               <id root="621499d7-5f3f-4f24-8b7d-888a76a7d852"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph>Alprazolam Tablets, USP are available as:</paragraph>
                  <list listType="unordered" styleCode="disc">
                     <item>0.25 mg: White to off white, oval, biconvex tablets with break line on one side and debossed "B704" on the other side.</item>
                     <item>0.5 mg: Light orange to orange, oval, biconvex tablets with break line on one side and debossed "B705" on the other side.</item>
                     <item>1 mg: Light blue to blue, oval, biconvex tablets with break line on one side and debossed "B706" on the other side.</item>
                     <item>2 mg: Light blue to blue, rectangle tablets with three break lines on one side and two notches in between two break lines, debossed "B707" on the other side.</item>
                  </list>
               </text>
               <effectiveTime value="20210412"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Tablets: 0.25 mg, 0.5 mg, 1 mg, and 2 mg (<linkHtml href="#S3">3</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S4">
               <id root="4839583d-fae9-491a-abb1-74c9ac977a0e"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <text>
                  <paragraph>Alprazolam tablets are contraindicated in patients:</paragraph>
                  <list listType="unordered" styleCode="disc">
                     <item>with known hypersensitivity to alprazolam or other benzodiazepines. Angioedema has been reported <content styleCode="italics">[see <linkHtml href="#S6.2">Adverse Reactions (6.2)</linkHtml>]</content>.</item>
                     <item>taking strong cytochrome P450 3A (CYP3A) inhibitors (e.g., ketoconazole, itraconazole), except ritonavir <content styleCode="italics">[see <linkHtml href="#S2.6">Dosage and Administration (2.6)</linkHtml>, <linkHtml href="#S5.5">Warnings and Precautions (5.5)</linkHtml>, <linkHtml href="#S7.1">Drug Interactions (7.1)</linkHtml>]</content>.</item>
                  </list>
               </text>
               <effectiveTime value="20210412"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="disc">
                           <item>Known hypersensitivity to alprazolam or other benzodiazepines. (<linkHtml href="#S4">4</linkHtml>)</item>
                           <item>Concomitant use with strong cytochrome P450 3A (CYP3A) inhibitors, except ritonavir. (<linkHtml href="#S4">4</linkHtml>, <linkHtml href="#S5.5">5.5</linkHtml>, <linkHtml href="#S7.1">7.1</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S5">
               <id root="07fd0b8a-f3dd-4624-b73c-ebbe83b9e659"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <effectiveTime value="20210412"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="disc">
                           <item>Effects on Driving and Operating Machinery: Patients receiving alprazolam tablets should be cautioned against operating machinery or driving a motor vehicle, as well as avoiding concomitant use of alcohol and other central nervous system (CNS) depressant drugs. (<linkHtml href="#S5.4">5.4</linkHtml>)</item>
                           <item>Neonatal Sedation and Withdrawal Syndrome (NOWS): Use of alprazolam tablets during pregnancy can result in neonatal sedation and neonatal withdrawal syndrome. (<linkHtml href="#S5.5">5.5</linkHtml>, <linkHtml href="#S8.1">8.1</linkHtml>)</item>
                           <item>Patients with Depression: Exercise caution in patients with signs or symptoms of depression. Prescribe the least number of tablets feasible to avoid intentional overdosage. (<linkHtml href="#S5.7">5.7</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S5.1">
                     <id root="930d64aa-2166-4873-97c3-df2d0df47aba"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1 Risks from Concomitant Use with Opioids</title>
                     <text>
                        <paragraph>Concomitant use of benzodiazepines, including alprazolam tablets, and opioids may result in profound sedation, respiratory depression, coma, and death. Because of these risks, reserve concomitant prescribing of these drugs in patients for whom alternative treatment options are inadequate.</paragraph>
                        <paragraph>Observational studies have demonstrated that concomitant use of opioid analgesics and benzodiazepines increases the risk of drug-related mortality compared to use of opioids alone. If a decision is made to prescribe alprazolam tablets concomitantly with opioids, prescribe the lowest effective dosages and minimum durations of concomitant use, and follow patients closely for signs and symptoms of respiratory depression and sedation. In patients already receiving an opioid analgesic, prescribe a lower initial dose of alprazolam tablets than indicated in the absence of an opioid and titrate based on clinical response. If an opioid is initiated in a patient already taking alprazolam tablets, prescribe a lower initial dose of the opioid and titrate based upon clinical response.</paragraph>
                        <paragraph>Advise both patients and caregivers about the risks of respiratory depression and sedation when alprazolam tablets is used with opioids. Advise patients not to drive or operate heavy machinery until the effects of concomitant use with the opioid have been determined <content styleCode="italics">[see <linkHtml href="#S7.1">Drug Interactions (7.1)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20210412"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.2">
                     <id root="ee8e150f-a78a-4074-9ade-e5b9f634037f"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2 Abuse, Misuse, and Addiction</title>
                     <text>
                        <paragraph>
                           <content styleCode="xmChange">The use of benzodiazepines, including alprazolam tablets, exposes users to the risks of abuse, misuse, and addiction, which can lead to overdose or death. Abuse and misuse of benzodiazepines often (but not always) involve the use of doses greater than the maximum recommended dosage and commonly involve concomitant use of other medications, alcohol, and/or illicit substances, which is associated with an increased frequency of serious adverse outcomes, including respiratory depression, overdose, or death <content styleCode="italics">[see <linkHtml href="#S9.2">Drug Abuse and Dependence (9.2)</linkHtml>]</content>.</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange">Before prescribing alprazolam tablets and throughout treatment, assess each patient's risk for abuse, misuse, and addiction (e.g., using a standardized screening tool). Use of alprazolam tablets, particularly in patients at elevated risk, necessitates counseling about the risks and proper use of alprazolam tablets along with monitoring for signs and symptoms of abuse, misuse, and addiction. Prescribe the lowest effective dosage; avoid or minimize concomitant use of CNS depressants and other substances associated with abuse, misuse, and addiction (e.g., opioid analgesics, stimulants); and advise patients on the proper disposal of unused drug. If a substance use disorder is suspected, evaluate the patient and institute (or refer them for) early treatment, as appropriate.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20210412"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.3">
                     <id root="e2a56e5b-7f37-4e53-8f66-7063c0ac3cae"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.3 Dependence and Withdrawal Reactions</title>
                     <text>
                        <paragraph>
                           <content styleCode="xmChange">To reduce the risk of withdrawal reactions, use a gradual taper to discontinue alprazolam tablets or reduce the dosage (a patient-specific plan should be used to taper the dose) <content styleCode="italics">[see <linkHtml href="#S2.3">Dosage and Administration (2.3)</linkHtml>]</content>.</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange">Patients at an increased risk of withdrawal adverse reactions after benzodiazepine discontinuation or rapid dosage reduction include those who take higher dosages, and those who have had longer durations of use.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20210412"/>
                     <component>
                        <section>
                           <id root="7333ba38-d566-4504-9aea-e349a6c3d7a3"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="xmChange">
                                    <content styleCode="underline">Acute Withdrawal Reactions</content>
                                 </content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="xmChange">The continued use of benzodiazepines, including alprazolam tablets, may lead to clinically significant physical dependence. Abrupt discontinuation or rapid dosage reduction of alprazolam tablets after continued use, or administration of flumazenil (a benzodiazepine antagonist) may precipitate acute withdrawal reactions, which can be life-threatening (e.g., seizures) <content styleCode="italics">[see <linkHtml href="#S9.3">Drug Abuse and Dependence (9.3)</linkHtml>]</content>.</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20210412"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="cf2af173-cddd-4d9f-90eb-f4bbb712cc9a"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="xmChange">
                                    <content styleCode="underline">Protracted Withdrawal Syndrome</content>
                                 </content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="xmChange">In some cases, benzodiazepine users have developed a protracted withdrawal syndrome with withdrawal symptoms lasting weeks to more than 12 months <content styleCode="italics">[see <linkHtml href="#S9.3">Drug Abuse and Dependence (9.3)</linkHtml>]</content>.</content>
                              </paragraph>
                              <paragraph>Certain adverse clinical events, some life-threatening, are a direct consequence of physical dependence to alprazolam tablets. These include a spectrum of withdrawal symptoms; the most important is seizure <content styleCode="italics">[see <linkHtml href="#S9.3">Drug Abuse and Dependence (9.3)</linkHtml>]</content>. Even after relatively short-term use at doses of â‰¤ 4 mg/day, there is some risk of dependence. Spontaneous reporting system data suggest that the risk of dependence and its severity appear to be greater in patients treated with doses greater than 4 mg/day and for long periods (more than 12 weeks). However, in a controlled postmarketing discontinuation study of panic disorder patients who received alprazolam tablets, the duration of treatment (3 months compared to 6 months) had no effect on the ability of patients to taper to zero dose. In contrast, patients treated with doses of alprazolam tablets greater than 4 mg/day had more difficulty tapering to zero dose than those treated with less than 4 mg/day.</paragraph>
                              <paragraph>In a controlled clinical trial in which 63 patients were randomized to alprazolam tablets and where withdrawal symptoms were specifically sought, the following were identified as symptoms of withdrawal: heightened sensory perception, impaired concentration, dysosmia, clouded sensorium, paresthesias, muscle cramps, muscle twitch, diarrhea, blurred vision, appetite decrease, and weight loss. Other symptoms, such as anxiety and insomnia, were frequently seen during discontinuation, but it could not be determined if they were due to return of illness, rebound, or withdrawal.</paragraph>
                           </text>
                           <effectiveTime value="20210412"/>
                           <component>
                              <section>
                                 <id root="adbb1694-74e8-42a0-a03f-6ac270cb6317"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>Interdose Symptoms</paragraph>
                                    <paragraph>Early morning anxiety and emergence of anxiety symptoms between doses of alprazolam tablets have been reported in patients with panic disorder taking prescribed maintenance doses. These symptoms may reflect the development of tolerance or a time interval between doses which is longer than the duration of clinical action of the administered dose. In either case, it is presumed that the prescribed dose is not sufficient to maintain plasma levels above those needed to prevent relapse, rebound, or withdrawal symptoms over the entire course of the interdosing interval.</paragraph>
                                 </text>
                                 <effectiveTime value="20210412"/>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S5.4">
                     <id root="01c78b1c-5abe-468a-a51f-f7250fa5a431"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.4 Effects on Driving and Operating Machinery</title>
                     <text>
                        <paragraph>Because of its CNS depressant effects, patients receiving alprazolam tablets should be cautioned against engaging in hazardous occupations or activities requiring complete mental alertness such as operating machinery or driving a motor vehicle. For the same reason, patients should be cautioned about the concomitant use of alcohol and other CNS depressant drugs during treatment with alprazolam tablets <content styleCode="italics">[see <linkHtml href="#S7.1">Drug Interactions (7.1)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20210412"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.5">
                     <id root="de55a15e-d828-4923-bdb5-84f204637ba4"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.5 Neonatal Sedation and Withdrawal Syndrome</title>
                     <text>
                        <paragraph>Use of alprazolam tablets during later stages of pregnancy can result in sedation (respiratory depression, lethargy, hypotonia) and withdrawal symptoms (hyperreflexia, irritability, restlessness, tremors, inconsolable crying, and feeding difficulties) in the neonate. Observe newborns for signs of sedation and neonatal withdrawal syndrome and manage accordingly <content styleCode="italics">[see <linkHtml href="#S8.1">Use in Specific Populations (8.1)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20210412"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.6">
                     <id root="7681f70a-ff0c-4dab-a47b-c35bcd032ee2"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.6 Interaction with Drugs that Inhibit Metabolism via Cytochrome P450 3A</title>
                     <text>
                        <paragraph>The initial step in alprazolam metabolism is hydroxylation catalyzed by cytochrome P450 3A (CYP3A). Drugs that inhibit this metabolic pathway may have a profound effect on the clearance of alprazolam.</paragraph>
                     </text>
                     <effectiveTime value="20210412"/>
                     <component>
                        <section>
                           <id root="5ffa2942-ee55-4751-839d-a943081f8b91"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Strong CYP3A Inhibitors</content>
                              </paragraph>
                              <paragraph>Alprazolam tablets are contraindicated in patients receiving strong inhibitors of CYP3A (such as azole antifungal agents), except ritonavir <content styleCode="italics">[see <linkHtml href="#S4">Contraindications (4)</linkHtml>]</content>. Ketoconazole and itraconazole have been shown in vivo to increase plasma alprazolam concentrations 3.98 fold and 2.70 fold, respectively.</paragraph>
                              <paragraph>Dosage adjustment is necessary when alprazolam tablets and ritonavir are initiated concomitantly or when ritonavir is added to a stable dosage of alprazolam tablets <content styleCode="italics">[see <linkHtml href="#S2.6">Dosage and Administration (2.6)</linkHtml>, <linkHtml href="#S7.1">Drug Interactions (7.1)</linkHtml>]</content>.</paragraph>
                              <paragraph>Drugs demonstrated to be CYP3A inhibitors on the basis of clinical studies involving alprazolam: nefazodone, fluvoxamine, and cimetidine <content styleCode="italics">[see <linkHtml href="#S7.1">Drug Interaction (7.1)</linkHtml>, <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>]</content>. Use caution and consider dose reduction of alprazolam tablets, as appropriate, during co-administration with these drugs.</paragraph>
                           </text>
                           <effectiveTime value="20210412"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S5.7">
                     <id root="80d62c09-05c3-46f6-9e78-68728b56280e"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.7 Patients with Depression</title>
                     <text>
                        <paragraph>Benzodiazepines may worsen depression. Panic disorder has been associated with primary and secondary major depressive disorders and increased reports of suicide among untreated patients. Consequently, appropriate precautions (e.g., limiting the total prescription size and increased monitoring for suicidal ideation) should be considered in patients with depression.</paragraph>
                     </text>
                     <effectiveTime value="20210412"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.8">
                     <id root="c9b1545f-86fa-47d5-bec9-a79db51675ec"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.8 Mania</title>
                     <text>
                        <paragraph>Episodes of hypomania and mania have been reported in association with the use of alprazolam tablets in patients with depression <content styleCode="italics">[see <linkHtml href="#S6.2">Adverse Reactions (6.2)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20210412"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.9">
                     <id root="231411d8-9c23-4d75-b375-518b3a2499c4"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.9 Risk in Patients with Impaired Respiratory Function</title>
                     <text>
                        <paragraph>There have been reports of death in patients with severe pulmonary disease shortly after the initiation of treatment with alprazolam tablets. Closely monitor patients with impaired respiratory function. If signs and symptoms of respiratory depression, hypoventilation, or apnea occur, discontinue alprazolam tablets.</paragraph>
                     </text>
                     <effectiveTime value="20210412"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S6">
               <id root="8e24ea38-a5f3-49e5-83a2-f0211f761219"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <text>
                  <paragraph>The following clinically significant adverse reactions are described elsewhere in the labeling:</paragraph>
                  <list listType="unordered" styleCode="disc">
                     <item>Risks from Concomitant Use with Opioids <content styleCode="italics">[see <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>]</content>
                     </item>
                     <item>Abuse, Misuse, and Addiction <content styleCode="italics">[see <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>]</content>
                     </item>
                     <item>Dependence and Withdrawal Reactions <content styleCode="italics">[see <linkHtml href="#S5.3">Warnings and Precautions (5.3)</linkHtml>]</content>
                     </item>
                     <item>Effects on Driving and Operating Machinery <content styleCode="italics">[see <linkHtml href="#S5.4">Warnings and Precautions (5.4)</linkHtml>]</content>
                     </item>
                     <item>Neonatal Sedation and Withdrawal Syndrome <content styleCode="italics">[see <linkHtml href="#S5.5">Warnings and Precautions (5.5)</linkHtml>]</content>
                     </item>
                     <item>Patients with Depression <content styleCode="italics">[see <linkHtml href="#S5.7">Warnings and Precautions (5.7)</linkHtml>]</content>
                     </item>
                     <item>Risks in Patients with Impaired Respiratory Function <content styleCode="italics">[see <linkHtml href="#S5.9">Warnings and Precautions (5.9)</linkHtml>]</content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20210412"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>The most common adverse reactions reported in clinical trials for generalized anxiety disorder and panic disorder (incidence â‰¥5% and at least twice that of placebo) include: impaired coordination, hypotension, dysarthria, and increased libido. (<linkHtml href="#S6.1">6.1</linkHtml>)</paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Breckenridge Pharmaceutical, Inc. at 1-800-367-3395 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S6.1">
                     <id root="22344526-ed64-47dc-b888-d526a0c63444"/>
                     <code code="90374-0" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL TRIALS EXPERIENCE SECTION"/>
                     <title>6.1	Clinical Trials Experience</title>
                     <text>
                        <paragraph>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</paragraph>
                        <paragraph>The data in the two tables below are estimates of adverse reaction incidence among adult patients who participated in:</paragraph>
                        <list listType="unordered" styleCode="disc">
                           <item>4-week placebo-controlled clinical studies with alprazolam tablets dosages up to 4 mg per day for the acute treatment of generalized anxiety disorder (Table 1)</item>
                           <item>Short-term (up to 10 weeks) placebo-controlled clinical studies with alprazolam tablets dosages up to 10 mg per day for panic disorder, with or without agoraphobia (Table 2).</item>
                        </list>
                        <table width="75%">
                           <caption>Table 1: Adverse Reactions Occurring in â‰¥1% in Alprazolam Tablets-treated Patients and Greater than Placebo-treated Patients in Placebo-Controlled Trials for Generalized Anxiety</caption>
                           <col width="50%" align="left" valign="top"/>
                           <col width="25%" align="center" valign="top"/>
                           <col width="25%" align="center" valign="top"/>
                           <thead>
                              <tr>
                                 <th styleCode="Lrule Rrule"/>
                                 <th styleCode="Rrule">Alprazolam tablets<br/>n=565</th>
                                 <th styleCode="Rrule">Placebo<br/>n=505</th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">
                                    <content styleCode="bold">Nervous system disorders</content>
                                 </td>
                                 <td styleCode="Rrule"/>
                                 <td styleCode="Rrule"/>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Drowsiness</td>
                                 <td styleCode="Rrule">41%</td>
                                 <td styleCode="Rrule">22%</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Light-headedness</td>
                                 <td styleCode="Rrule">21%</td>
                                 <td styleCode="Rrule">19%</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Dizziness</td>
                                 <td styleCode="Rrule">2%</td>
                                 <td styleCode="Rrule">1%</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Akathisia</td>
                                 <td styleCode="Rrule">2%</td>
                                 <td styleCode="Rrule">1%</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">
                                    <content styleCode="bold">Gastrointestinal disorders</content>
                                 </td>
                                 <td styleCode="Rrule"/>
                                 <td styleCode="Rrule"/>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Dry mouth</td>
                                 <td styleCode="Rrule">15%</td>
                                 <td styleCode="Rrule">13%</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Increased salivation</td>
                                 <td styleCode="Rrule">4%</td>
                                 <td styleCode="Rrule">2%</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">
                                    <content styleCode="bold">Cardiovascular disorders</content>
                                 </td>
                                 <td styleCode="Rrule"/>
                                 <td styleCode="Rrule"/>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Hypotension</td>
                                 <td styleCode="Rrule">5%</td>
                                 <td styleCode="Rrule">2%</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">
                                    <content styleCode="bold">Skin and subcutaneous tissue disorders</content>
                                 </td>
                                 <td styleCode="Rrule"/>
                                 <td styleCode="Rrule"/>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule">Dermatitis/allergy</td>
                                 <td styleCode="Rrule">4%</td>
                                 <td styleCode="Rrule">3%</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>In addition to the adverse reactions (i.e., greater than 1%) enumerated in the table above for patients with generalized anxiety disorder, the following adverse reactions have been reported in association with the use of benzodiazepines: dystonia, irritability, concentration difficulties, anorexia, transient amnesia or memory impairment, loss of coordination, fatigue, seizures, sedation, slurred speech, jaundice, musculoskeletal weakness, pruritus, diplopia, dysarthria, changes in libido, menstrual irregularities, incontinence and urinary retention.</paragraph>
                        <table width="75%">
                           <caption>Table 2: Adverse Reactions Occurring in â‰¥1% in Alprazolam Tablets-treated Patients and Greater than Placebo-treated Patients in Placebo-Controlled Trials (Up to 10 Weeks) for Panic Disorder</caption>
                           <col width="50%" align="left" valign="top"/>
                           <col width="25%" align="center" valign="top"/>
                           <col width="25%" align="center" valign="top"/>
                           <thead>
                              <tr>
                                 <th styleCode="Lrule Rrule"/>
                                 <th styleCode="Rrule">Alprazolam Tablets<br/>n=1388</th>
                                 <th styleCode="Rrule">Placebo<br/>n=1231</th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Â Â Drowsiness</td>
                                 <td styleCode="Rrule">77%</td>
                                 <td styleCode="Rrule">43%</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Â Â Fatigue and Tiredness</td>
                                 <td styleCode="Rrule">49%</td>
                                 <td styleCode="Rrule">42%</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Â Â Impaired Coordination</td>
                                 <td styleCode="Rrule">40%</td>
                                 <td styleCode="Rrule">18%</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Â Â Irritability</td>
                                 <td styleCode="Rrule">33%</td>
                                 <td styleCode="Rrule">30%</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Â Â Memory Impairment</td>
                                 <td styleCode="Rrule">33%</td>
                                 <td styleCode="Rrule">22%</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Â Â Cognitive Disorder</td>
                                 <td styleCode="Rrule">29%</td>
                                 <td styleCode="Rrule">21%</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Â Â Decreased Libido</td>
                                 <td styleCode="Rrule">14%</td>
                                 <td styleCode="Rrule">8%</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Â Â Dysarthria</td>
                                 <td styleCode="Rrule">23%</td>
                                 <td styleCode="Rrule">6%</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Â Â Confusional state</td>
                                 <td styleCode="Rrule">10%</td>
                                 <td styleCode="Rrule">8%</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Â Â Increased libido</td>
                                 <td styleCode="Rrule">8%</td>
                                 <td styleCode="Rrule">4%</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Â Â Change in libido (not specified)</td>
                                 <td styleCode="Rrule">7%</td>
                                 <td styleCode="Rrule">6%</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Â Â Disinhibition</td>
                                 <td styleCode="Rrule">3%</td>
                                 <td styleCode="Rrule">2%</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Â Â Talkativeness</td>
                                 <td styleCode="Rrule">2%</td>
                                 <td styleCode="Rrule">1%</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Â Â Derealization</td>
                                 <td styleCode="Rrule">2%</td>
                                 <td styleCode="Rrule">1%</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">
                                    <content styleCode="bold">Gastrointestinal disorders</content>
                                 </td>
                                 <td styleCode="Rrule"/>
                                 <td styleCode="Rrule"/>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Â Â Constipation</td>
                                 <td styleCode="Rrule">26%</td>
                                 <td styleCode="Rrule">15%</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Â Â Increased salivation</td>
                                 <td styleCode="Rrule">6%</td>
                                 <td styleCode="Rrule">4%</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">
                                    <content styleCode="bold">Skin and subcutaneous tissue disorders</content>
                                 </td>
                                 <td styleCode="Rrule"/>
                                 <td styleCode="Rrule"/>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Â Â Rash</td>
                                 <td styleCode="Rrule">11%</td>
                                 <td styleCode="Rrule">8%</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">
                                    <content styleCode="bold">Other</content>
                                 </td>
                                 <td styleCode="Rrule"/>
                                 <td styleCode="Rrule"/>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Â Â Increased appetite</td>
                                 <td styleCode="Rrule">33%</td>
                                 <td styleCode="Rrule">23%</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Â Â Decreased appetite</td>
                                 <td styleCode="Rrule">28%</td>
                                 <td styleCode="Rrule">24%</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Â Â Weight gain</td>
                                 <td styleCode="Rrule">27%</td>
                                 <td styleCode="Rrule">18%</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Â Â Weight loss</td>
                                 <td styleCode="Rrule">23%</td>
                                 <td styleCode="Rrule">17%</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Â Â Micturition difficulties</td>
                                 <td styleCode="Rrule">12%</td>
                                 <td styleCode="Rrule">9%</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Â Â Menstrual disorders</td>
                                 <td styleCode="Rrule">11%</td>
                                 <td styleCode="Rrule">9%</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Â Â Sexual dysfunction</td>
                                 <td styleCode="Rrule">7%</td>
                                 <td styleCode="Rrule">4%</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule">Â Â Incontinence</td>
                                 <td styleCode="Rrule">2%</td>
                                 <td styleCode="Rrule">1%</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>In addition to the reactions (i.e., greater than 1%) enumerated in the table above for patients with panic disorder, the following adverse reactions have been reported in association with the use of alprazolam tablets: seizures, hallucinations, depersonalization, taste alterations, diplopia, elevated bilirubin, elevated hepatic enzymes, and jaundice.</paragraph>
                     </text>
                     <effectiveTime value="20210412"/>
                     <component>
                        <section>
                           <id root="8b255d24-5b89-48a6-9f16-87c0bfc0f076"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Adverse Reactions Reported as Reasons for Discontinuation in Treatment of Panic Disorder in Placebo-Controlled Trials</content>
                              </paragraph>
                              <paragraph>In a larger database comprised of both controlled and uncontrolled studies in which 641 patients received alprazolam tablets, discontinuation-emergent symptoms which occurred at a rate of over 5% in patients treated with alprazolam tablets and at a greater rate than the placebo-treated group are shown in Table 3.</paragraph>
                              <table width="75%">
                                 <caption>Table 3: Discontinuation-Emergent Symptom Incidence Reported in â‰¥5% of Alprazolam Tablets-treated Patients and &gt; Placebo-treated Patients</caption>
                                 <col width="40%" align="left" valign="top"/>
                                 <col width="60%" align="center" valign="top"/>
                                 <thead>
                                    <tr>
                                       <th styleCode="Lrule Rrule"/>
                                       <th styleCode="Rrule">Alprazolam tablets-treated Patients n=641</th>
                                    </tr>
                                 </thead>
                                 <tfoot>
                                    <tr>
                                       <td align="left" colspan="2">n=number of patients.</td>
                                    </tr>
                                 </tfoot>
                                 <tbody>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">
                                          <content styleCode="bold">Nervous system disorders</content>
                                       </td>
                                       <td styleCode="Rrule"/>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Insomnia</td>
                                       <td styleCode="Rrule">29.5%</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Light-headedness</td>
                                       <td styleCode="Rrule">19.3%</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Abnormal involuntary movement</td>
                                       <td styleCode="Rrule">17.3%</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Headache</td>
                                       <td styleCode="Rrule">17.0%</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Muscular twitching</td>
                                       <td styleCode="Rrule">6.9%</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Impaired coordination</td>
                                       <td styleCode="Rrule">6.6%</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Muscle tone disorders</td>
                                       <td styleCode="Rrule">5.9%</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Weakness</td>
                                       <td styleCode="Rrule">5.8%</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">
                                          <content styleCode="bold">Psychiatric disorders</content>
                                       </td>
                                       <td styleCode="Rrule"/>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Anxiety</td>
                                       <td styleCode="Rrule">19.2%</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Fatigue and Tiredness</td>
                                       <td styleCode="Rrule">18.4%</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Irritability</td>
                                       <td styleCode="Rrule">10.5%</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Cognitive disorder</td>
                                       <td styleCode="Rrule">10.3%</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Memory impairment</td>
                                       <td styleCode="Rrule">5.5%</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Depression</td>
                                       <td styleCode="Rrule">5.1%</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Confusional state</td>
                                       <td styleCode="Rrule">5.0%</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">
                                          <content styleCode="bold">Gastrointestinal disorders</content>
                                       </td>
                                       <td styleCode="Rrule"/>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Nausea/Vomiting</td>
                                       <td styleCode="Rrule">16.5%</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Diarrhea</td>
                                       <td styleCode="Rrule">13.6%</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Decreased salivation</td>
                                       <td styleCode="Rrule">10.6%</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">
                                          <content styleCode="bold">Metabolism and nutrition disorders</content>
                                       </td>
                                       <td styleCode="Rrule"/>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Weight loss</td>
                                       <td styleCode="Rrule">13.3%</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Decreased appetite</td>
                                       <td styleCode="Rrule">12.8%</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">
                                          <content styleCode="bold">Dermatological disorders</content>
                                       </td>
                                       <td styleCode="Rrule"/>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Sweating</td>
                                       <td styleCode="Rrule">14.4%</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">
                                          <content styleCode="bold">Cardiovascular disorders</content>
                                       </td>
                                       <td styleCode="Rrule"/>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Tachycardia</td>
                                       <td styleCode="Rrule">12.2%</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">
                                          <content styleCode="bold">Special Senses</content>
                                       </td>
                                       <td styleCode="Rrule"/>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">Blurred vision</td>
                                       <td styleCode="Rrule">10.0%</td>
                                    </tr>
                                 </tbody>
                              </table>
                              <paragraph>There have also been reports of withdrawal seizures upon rapid decrease or abrupt discontinuation of alprazolam tablets <content styleCode="italics">[see <linkHtml href="#S5.2">Warning and Precautions (5.2)</linkHtml> and <linkHtml href="#S9.3">Drug Abuse and Dependence (9.3)</linkHtml>]</content>. Paradoxical reactions such as stimulation, increased muscle spasticity, sleep disturbances, hallucinations, and other adverse behavioral effects such as agitation, rage, irritability, and aggressive or hostile behavior have been reported rarely. In many of the spontaneous case reports of adverse behavioral effects, patients were receiving other CNS drugs concomitantly and/or were described as having underlying psychiatric conditions. Should any of the above events occur, alprazolam should be discontinued. Isolated published reports involving small numbers of patients have suggested that patients who have borderline personality disorder, a prior history of violent or aggressive behavior, or alcohol or substance abuse may be at risk for such events. Instances of irritability, hostility, and intrusive thoughts have been reported during discontinuation of alprazolam in patients with post-traumatic stress disorder.</paragraph>
                           </text>
                           <effectiveTime value="20210412"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S6.2">
                     <id root="918a9548-69ba-4c67-bb5f-fcd57f79cdc5"/>
                     <code code="90375-7" codeSystem="2.16.840.1.113883.6.1" displayName="POSTMARKETING EXPERIENCE SECTION"/>
                     <title>6.2 Postmarketing Experience</title>
                     <text>
                        <paragraph>The following adverse reactions have been identified during postapproval use of alprazolam tablets. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Endocrine disorders:</content> Hyperprolactinemia</paragraph>
                        <paragraph>
                           <content styleCode="italics">General disorders and administration site conditions:</content> Edema peripheral</paragraph>
                        <paragraph>
                           <content styleCode="italics">Hepatobiliary disorders:</content> Hepatitis, hepatic failure</paragraph>
                        <paragraph>
                           <content styleCode="italics">Investigations:</content> Liver enzyme elevations</paragraph>
                        <paragraph>
                           <content styleCode="italics">Psychiatric disorders:</content> Hypomania, mania</paragraph>
                        <paragraph>
                           <content styleCode="italics">Reproductive system and breast disorders:</content> Gynecomastia, galactorrhea</paragraph>
                        <paragraph>
                           <content styleCode="italics">Skin and subcutaneous tissue disorders:</content> Photosensitivity reaction, angioedema, Stevens-Johnson syndrome</paragraph>
                     </text>
                     <effectiveTime value="20210412"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S7">
               <id root="11befe51-01d2-4419-a63c-e62f53cbecfe"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7 DRUG INTERACTIONS</title>
               <effectiveTime value="20210412"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="disc">
                           <item>Use with Opioids: Increase the risk of respiratory depression. (<linkHtml href="#S7.1">7.1</linkHtml>)</item>
                           <item>Use with Other CNS Depressants: Produces additive CNS depressant effects. (<linkHtml href="#S7.1">7.1</linkHtml>)</item>
                           <item>Use with Digoxin: Increase the risk of digoxin toxicity. (<linkHtml href="#S7.1">7.1</linkHtml>)</item>
                           <item>Use with CYP3A Inhibitors (except ritonavir): Increase the risk of adverse reactions of alprazolam. (<linkHtml href="#S4">4</linkHtml>, <linkHtml href="#S5.6">5.6</linkHtml>, <linkHtml href="#S7.1">7.1</linkHtml>)</item>
                           <item>Use with CYP3A Inducers: Increase the risk of reduced efficacy of alprazolam. (<linkHtml href="#S7.1">7.1</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S7.1">
                     <id root="f6e2669a-d9f4-4a2d-8219-6702e2a6752b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.1 Drugs Having Clinically Important Interactions with Alprazolam Tablets</title>
                     <text>
                        <paragraph>Table 4 includes clinically significant drug interactions with alprazolam tablets <content styleCode="italics">[see <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>]</content>.</paragraph>
                        <table width="100%">
                           <caption>Table 4: Clinically Significant Drug Interactions with Alprazolam Tablets</caption>
                           <col width="20%" align="left" valign="top"/>
                           <col width="80%" align="left" valign="top"/>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" colspan="2">
                                    <content styleCode="bold">Opioids</content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Clinical implication</td>
                                 <td styleCode="Rrule">The concomitant use of benzodiazepines and opioids increases the risk of respiratory depression because of actions at different receptor sites in the CNS that control respiration. Benzodiazepines interact at gamma-aminobutyric acid (GABA<sub>A</sub>) sites and opioids interact primarily at mu receptors. When benzodiazepines and opioids are combined, the potential for benzodiazepines to significantly worsen opioid-related respiratory depression exists.</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Prevention or management</td>
                                 <td styleCode="Rrule">Limit dosage and duration of concomitant use of alprazolam tablets and opioids, and monitor patients closely for respiratory depression and sedation <content styleCode="italics">[see <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>]</content>.</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Examples</td>
                                 <td styleCode="Rrule">Morphine, buprenorphine, hydromorphone, oxymorphone, oxycodone, fentanyl, methadone, alfentanil, butorpenol, codeine, dihydrocodeine, meperidine, pentazocine, remifentanil, sufentanil, tapentadol, tramadol.</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" colspan="2">
                                    <content styleCode="bold">CNS Depressants</content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Clinical implication</td>
                                 <td styleCode="Rrule">The benzodiazepines, including alprazolam, produce additive CNS depressant effects when coadministered with other CNS depressants.</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Prevention or management</td>
                                 <td styleCode="Rrule">Limit dosage and duration of alprazolam tablets during concomitant use with CNS depressants <content styleCode="italics">[see <linkHtml href="#S5.3">Warnings and Precautions (5.3)</linkHtml>]</content>.</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Examples</td>
                                 <td styleCode="Rrule">Psychotropic medications, anticonvulsants, antihistaminics, ethanol, and other drugs which themselves produce CNS depression.</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" colspan="2">
                                    <content styleCode="bold">Strong Inhibitors of CYP3A (except ritonavir)</content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Clinical implication</td>
                                 <td styleCode="Rrule">Concomitant use of alprazolam tablets with strong CYP3A inhibitors has a profound effect on the clearance of alprazolam, resulting in increased concentrations of alprazolam and increased risk of adverse reactions <content styleCode="italics">[see <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>]</content>.</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Prevention or management</td>
                                 <td styleCode="Rrule">Concomitant use of alprazolam tablets with a strong CYP3A4 inhibitor (except ritonavir) is contraindicated <content styleCode="italics">[see <linkHtml href="#S4">Contraindications (4)</linkHtml>, <linkHtml href="#S5.5">Warnings and Precautions (5.5)</linkHtml>]</content>.</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Examples</td>
                                 <td styleCode="Rrule">Ketoconazole, itraconazole, clarithromycin</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" colspan="2">
                                    <content styleCode="bold">Moderate or Weak Inhibitors of CYP3A</content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Clinical implication</td>
                                 <td styleCode="Rrule">Concomitant use of alprazolam tablets with CYP3A inhibitors may increase the concentrations of alprazolam tablets, resulting in increased risk of adverse reactions of alprazolam <content styleCode="italics">[see <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>]</content>.</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Prevention or management</td>
                                 <td styleCode="Rrule">Avoid use and consider appropriate dose reduction when alprazolam tablets is coadministered with a moderate or weak CYP3A inhibitor <content styleCode="italics">[see <linkHtml href="#S5.5">Warnings and Precautions (5.5)</linkHtml>]</content>.</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Examples</td>
                                 <td styleCode="Rrule">Nefazodone, fluvoxamine, cimetidine, erythromycin</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" colspan="2">
                                    <content styleCode="bold">CYP3A Inducers</content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Clinical implication</td>
                                 <td styleCode="Rrule">Concomitant use of CYP3A inducers can increase alprazolam metabolism and therefore can decease plasma levels of alprazolam <content styleCode="italics">[see <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>]</content>.</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Prevention or management</td>
                                 <td styleCode="Rrule">Caution is recommended during coadministration with alprazolam tablets.</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Examples</td>
                                 <td styleCode="Rrule">Carbamazepine, phenytoin</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" colspan="2">
                                    <content styleCode="bold">Ritonavir</content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Clinical implication</td>
                                 <td styleCode="Rrule">Interactions involving ritonavir and alprazolam are complex and time dependent. Short term administration of ritonavir increased alprazolam exposure due to CYP3A4 inhibition. Following long term treatment of ritonavir (&gt;10 to 14 days), CYP3A4 induction offsets this inhibition. Alprazolam exposure was not meaningfully affected in the presence of ritonavir.</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Prevention or management</td>
                                 <td styleCode="Rrule">Reduce alprazolam tablets dosage when ritonavir and alprazolam are initiated concomitantly, or when ritonavir is added to a regimen where alprazolam is stabilized.<br/>Increase alprazolam tablets dosage to the target dosage after 10 to 14 days of dosing ritonavir and alprazolam tablets concomitantly. No dosage adjustment of alprazolam tablets is necessary in patients receiving ritonavir for more than 10 to14 days <content styleCode="italics">[see <linkHtml href="#S2.6">Dosage and Administration (2.6)</linkHtml>]</content>.<br/>Concomitant use of alprazolam tablets with a strong CYP3A inhibitor, except ritonavir, is contraindicated <content styleCode="italics">[see <linkHtml href="#S4">Contraindications (4)</linkHtml>, <linkHtml href="#S5.5">Warnings and Precautions (5.5)</linkHtml>]</content>.</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" colspan="2">
                                    <content styleCode="bold">Digoxin</content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Clinical implication</td>
                                 <td styleCode="Rrule">Increased digoxin concentrations have been reported when alprazolam was given, especially in geriatric patients( &gt;65 years of age).</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule">Prevention or management</td>
                                 <td styleCode="Rrule">In patients on digoxin therapy, measure serum digoxin concentrations before initiating alprazolam tablets. Continue monitoring digoxin serum concentration and toxicity frequently. Reduce the digoxin dose if necessary.</td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20210412"/>
                  </section>
               </component>
               <component>
                  <section ID="S7.2">
                     <id root="3b0c6c7c-4b9f-4f27-b8f7-3e3eca762579"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.2 Drug/Laboratory Test Interactions</title>
                     <text>
                        <paragraph>Although interactions between benzodiazepines and commonly employed clinical laboratory tests have occasionally been reported, there is no consistent pattern for a specific drug or specific test.</paragraph>
                     </text>
                     <effectiveTime value="20210412"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S8">
               <id root="ee3a2562-1626-4999-a2c3-628f9e7b9593"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <effectiveTime value="20210412"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Lactation:</content> Breastfeeding not recommended. (<linkHtml href="#S8.2">8.2</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S8.1">
                     <id root="3279ecb6-d869-4795-ba14-d4317868863d"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <effectiveTime value="20210412"/>
                     <component>
                        <section>
                           <id root="ff34518a-950b-45dd-afec-8edbdef3295d"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Pregnancy Exposure Registry</content>
                              </paragraph>
                              <paragraph>There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to alprazolam tablets during pregnancy. Healthcare providers are encouraged to register patients by calling the National Pregnancy Registry for Other Psychiatric Medications at 1-866-961-2388 or visiting online at https://womensmentalhealth.org/clinical-and-research-programs/pregnancyregistry/othermedications/.</paragraph>
                           </text>
                           <effectiveTime value="20210412"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="cd91fe98-74a5-4d4c-9eea-cff09903ca2b"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Risk Summary</content>
                              </paragraph>
                              <paragraph>Neonates born to mothers using benzodiazepines during the later stages of pregnancy have been reported to experience symptoms of sedation and neonatal withdrawal <content styleCode="italics">[see <linkHtml href="#S5.4">Warnings and Precautions (5.4)</linkHtml>, <linkHtml href="#Clinical">Clinical Considerations</linkHtml>)]</content>. Overall available data from published observational studies of pregnant women exposed to alprazolam have not established a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes <content styleCode="italics">(see <linkHtml href="#Data">Data</linkHtml>)</content>.</paragraph>
                              <paragraph>The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated risk of major birth defects and of miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.</paragraph>
                           </text>
                           <effectiveTime value="20210412"/>
                        </section>
                     </component>
                     <component>
                        <section ID="Clinical">
                           <id root="3a7fb36e-7034-4f61-9243-83b898b745df"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Clinical Considerations</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20210412"/>
                           <component>
                              <section>
                                 <id root="3ac2b479-de2b-4e18-b350-887670cc5fd2"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Fetal/Neonatal adverse reactions</content>
                                    </paragraph>
                                    <paragraph>Benzodiazepines cross the placenta and may produce respiratory depression and sedation in neonates. Monitor neonates exposed to benzodiazepines during pregnancy and labor for signs of sedation, respiratory depression, withdrawal, and feeding problems and manage accordingly <content styleCode="italics">[see <linkHtml href="#S5.4">Warnings and Precautions (5.4)</linkHtml>]</content>.</paragraph>
                                 </text>
                                 <effectiveTime value="20210412"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section ID="Data">
                           <id root="ba5b9d80-48f6-4c25-8895-73c40438dcaf"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Data</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20210412"/>
                           <component>
                              <section>
                                 <id root="30502ed1-9382-4eff-b8cd-46bc060e65d7"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Human Data</content>
                                    </paragraph>
                                    <paragraph>Published data from observational studies on the use of benzodiazepines during pregnancy do not report a clear association with benzodiazepines and major birth defects. Although early studies reported an increased risk of congenital malformations with diazepam and chlordiazepoxide, there was no consistent pattern noted. In addition, the majority of recent case-control and cohort studies of benzodiazepine use during pregnancy, which were adjusted for confounding exposures to alcohol, tobacco, and other medications, have not confirmed these findings. At this time, there is no clear evidence that alprazolam exposure in early pregnancy can cause major birth defects. Neonates exposed to benzodiazepines during the late third trimester of pregnancy or during labor have been reported to exhibit sedation and neonatal withdrawal symptoms.</paragraph>
                                 </text>
                                 <effectiveTime value="20210412"/>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S8.2">
                     <id root="1182738c-4c87-4890-9546-8f390542bf32"/>
                     <code code="77290-5" codeSystem="2.16.840.1.113883.6.1" displayName="LACTATION SECTION"/>
                     <title>8.2 Lactation</title>
                     <effectiveTime value="20210412"/>
                     <component>
                        <section>
                           <id root="b50ea581-6d8b-46f9-83e6-d77848a4e316"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Risk Summary</content>
                              </paragraph>
                              <paragraph>Limited data from published literature reports the presence of alprazolam in human breast milk. There are reports of sedation and withdrawal symptoms in breastfed neonates and infants exposed to alprazolam. The effects of alprazolam on lactation are unknown.</paragraph>
                              <paragraph>Because of the potential for serious adverse reactions, including sedation and withdrawal symptoms in breastfed neonates and infants, advise patients that breastfeeding is not recommended during treatment with alprazolam tablets.</paragraph>
                           </text>
                           <effectiveTime value="20210412"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S8.4">
                     <id root="e281eb76-708e-41e1-87e6-a5962daff5f8"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph>Safety and effectiveness of alprazolam tablets have not been established in pediatric patients.</paragraph>
                     </text>
                     <effectiveTime value="20210412"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.5">
                     <id root="150047a4-a23f-4686-94bd-3ef93e68293c"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use</title>
                     <text>
                        <paragraph>Alprazolam-treated geriatric patients had higher plasma concentrations of alprazolam (due to reduced clearance) compared to younger adult patients receiving the same doses. Therefore, dosage reduction of alprazolam tablets is recommended in geriatric patients <content styleCode="italics">[see <linkHtml href="#S2.4">Dosage and Administration (2.4)</linkHtml> and <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20210412"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.6">
                     <id root="b4add77f-e9e2-4478-bd71-ebf577a3d69c"/>
                     <code code="88829-7" codeSystem="2.16.840.1.113883.6.1" displayName="HEPATIC IMPAIRMENT SUBSECTION"/>
                     <title>8.6 Hepatic Impairment</title>
                     <text>
                        <paragraph>Patients with alcoholic liver disease exhibit a longer elimination half-life (19.7 hours), compared to healthy subjects (11.4 hours). This may be caused by decreased clearance of alprazolam in patients with alcoholic liver disease. Dosage reduction of alprazolam tablets is recommended in patients with hepatic impairment <content styleCode="italics">[see <linkHtml href="#S2.4">Dosage and Administration (2.4)</linkHtml>, <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20210412"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S9">
               <id root="99058b2e-726b-40b2-9a10-cc17c5e23684"/>
               <code code="42227-9" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG ABUSE AND DEPENDENCE SECTION"/>
               <title>9 DRUG ABUSE AND DEPENDENCE</title>
               <effectiveTime value="20210412"/>
               <component>
                  <section ID="S9.1">
                     <id root="3d2c159d-4bda-4aef-9751-046476aceaed"/>
                     <code code="34085-1" codeSystem="2.16.840.1.113883.6.1" displayName="CONTROLLED SUBSTANCE SECTION"/>
                     <title>9.1 Controlled Substance</title>
                     <text>
                        <paragraph>Alprazolam tablets contain alprazolam, which is a Schedule IV controlled substance.</paragraph>
                     </text>
                     <effectiveTime value="20210412"/>
                  </section>
               </component>
               <component>
                  <section ID="S9.2">
                     <id root="95a67a79-2f32-454f-b86e-430f3b48c047"/>
                     <code code="34086-9" codeSystem="2.16.840.1.113883.6.1" displayName="ABUSE SECTION"/>
                     <title>9.2 Abuse</title>
                     <text>
                        <paragraph>Alprazolam tablets are a benzodiazepine and a CNS depressant with a potential for abuse and addiction. Abuse is the intentional, non-therapeutic use of a drug, even once, for its desirable psychological or physiological effects. Misuse is the intentional use, for therapeutic purposes, of a drug by an individual in a way other than prescribed by a health care provider or for whom it was not prescribed. Drug addiction is a cluster of behavioral, cognitive, and physiological phenomena that may include a strong desire to take the drug, difficulties in controlling drug use (e.g., continuing drug use despite harmful consequences, giving a higher priority to drug use than other activities and obligations), and possible tolerance or physical dependence. Even taking benzodiazepines as prescribed may put patients at risk for abuse and misuse of their medication. Abuse and misuse of benzodiazepines may lead to addiction.</paragraph>
                        <paragraph>Abuse and misuse of benzodiazepines often (but not always) involve the use of doses greater than the maximum recommended dosage and commonly involve concomitant use of other medications, alcohol, and/or illicit substances, which is associated with an increased frequency of serious adverse outcomes, including respiratory depression, overdose, or death. Benzodiazepines are often sought by individuals who abuse drugs and other substances, and by individuals with addictive disorders <content styleCode="italics">[see <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>]</content>.</paragraph>
                        <paragraph>The following adverse reactions have occurred with benzodiazepine abuse and/or misuse: abdominal pain, amnesia, anorexia, anxiety, aggression, ataxia, blurred vision, confusion, depression, disinhibition, disorientation, dizziness, euphoria, impaired concentration and memory, indigestion, irritability, muscle pain, slurred speech, tremors, and vertigo.</paragraph>
                        <paragraph>The following severe adverse reactions have occurred with benzodiazepine abuse and/or misuse: delirium, paranoia, suicidal ideation and behavior, seizures, coma, breathing difficulty, and death. Death is more often associated with polysubstance use (especially benzodiazepines with other CNS depressants such as opioids and alcohol).</paragraph>
                     </text>
                     <effectiveTime value="20210412"/>
                  </section>
               </component>
               <component>
                  <section ID="S9.3">
                     <id root="a5a6d3cf-18e7-4e0a-874d-576ecc476749"/>
                     <code code="34087-7" codeSystem="2.16.840.1.113883.6.1" displayName="DEPENDENCE SECTION"/>
                     <title>9.3 Dependence</title>
                     <text>
                        <paragraph>Alprazolam tablets may produce physical dependence from continued therapy. Physical dependence is a state that develops as a result of physiological adaptation in response to repeated drug use, manifested by withdrawal signs and symptoms after abrupt discontinuation or a significant dose reduction of a drug. Abrupt discontinuation or rapid dosage reduction of benzodiazepines or administration of flumazenil, a benzodiazepine antagonist, may precipitate acute withdrawal reactions, including seizures, which can be life-threatening. Patients at an increased risk of withdrawal adverse reactions after benzodiazepine discontinuation or rapid dosage reduction include those who take higher dosages (i.e., higher and/or more frequent doses) and those who have had longer durations of use <content styleCode="italics">[see <linkHtml href="#S5.3">Warnings and Precautions (5.3)</linkHtml>]</content>.</paragraph>
                        <paragraph>To reduce the risk of withdrawal reactions, use a gradual taper to discontinue alprazolam tablets or reduce the dosage <content styleCode="italics">[see <linkHtml href="#S2.3">Dosage and Administration (2.3)</linkHtml>, <linkHtml href="#S5.3">Warnings and Precautions (5.3)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20210412"/>
                     <component>
                        <section>
                           <id root="6da64943-4c4b-41b4-b96d-9eb3e0b3c3be"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="italics">Acute Withdrawal Signs and Symptoms</content>
                              </paragraph>
                              <paragraph>Acute withdrawal signs and symptoms associated with benzodiazepines have included abnormal involuntary movements, anxiety, blurred vision, depersonalization, depression, derealization, dizziness, fatigue, gastrointestinal adverse reactions (e.g., nausea, vomiting, diarrhea, weight loss, decreased appetite), headache, hyperacusis, hypertension, irritability, insomnia, memory impairment, muscle pain and stiffness, panic attacks, photophobia, restlessness, tachycardia, and tremor. More severe acute withdrawal signs and symptoms, including life-threatening reactions, have included catatonia, convulsions, delirium tremens, depression, hallucinations, mania, psychosis, seizures, and suicidality.</paragraph>
                           </text>
                           <effectiveTime value="20210412"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="867aed9e-ce66-4e0b-b5f5-6c8ca450376e"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="italics">Protracted Withdrawal Syndrome</content>
                              </paragraph>
                              <paragraph>Protracted withdrawal syndrome associated with benzodiazepines is characterized by anxiety, cognitive impairment, depression, insomnia, formication, motor symptoms (e.g., weakness, tremor, muscle twitches), paresthesia, and tinnitus that persists beyond 4 to 6 weeks after initial benzodiazepine withdrawal. Protracted withdrawal symptoms may last weeks to more than 12 months. As a result, there may be difficulty in differentiating withdrawal symptoms from potential re-emergence or continuation of symptoms for which the benzodiazepine was being used.</paragraph>
                           </text>
                           <effectiveTime value="20210412"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="93635989-0e16-4cd0-bb47-e643e536c436"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Tolerance</content>
                              </paragraph>
                              <paragraph>Tolerance to alprazolam tablets may develop from continued therapy. Tolerance is a physiological state characterized by a reduced response to a drug after repeated administration (i.e., a higher dose of a drug is required to produce the same effect that was once obtained at a lower dose). Tolerance to the therapeutic effect of alprazolam tablets may develop; however, little tolerance develops to the amnestic reactions and other cognitive impairments caused by benzodiazepines.</paragraph>
                           </text>
                           <effectiveTime value="20210412"/>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S10">
               <id root="bbdb7d79-d465-492f-b74a-24c1be0ebec3"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10 OVERDOSAGE</title>
               <effectiveTime value="20210412"/>
               <component>
                  <section ID="S10.1">
                     <id root="da05f9dc-5e94-47f2-a7e9-f227559608d5"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>10.1 Clinical Experience</title>
                     <text>
                        <paragraph>Manifestations of alprazolam overdosage include somnolence, confusion, impaired coordination, diminished reflexes, and coma. Death has been reported in association with overdoses of alprazolam by itself, as it has with other benzodiazepines. In addition, fatalities have been reported in patients who have overdosed with a combination of a single benzodiazepine, including alprazolam, and alcohol; alcohol levels seen in some of these patients have been lower than those usually associated with alcohol-induced fatality.</paragraph>
                     </text>
                     <effectiveTime value="20210412"/>
                  </section>
               </component>
               <component>
                  <section ID="S10.2">
                     <id root="517f0472-fdd1-4d7d-ae32-013e9bebcd57"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>10.2 Management of Overdose</title>
                     <text>
                        <paragraph>In case of an overdosage, consult a Certified Poison Control Center at 1-800-222-1222 for latest recommendations.</paragraph>
                        <paragraph>As in all cases of drug overdosage, respiration, pulse rate, and blood pressure should be monitored. General supportive measures should be employed, along with immediate gastric lavage. Intravenous fluids should be administered and an adequate airway maintained. As with the management of intentional overdosing with any drug, it should be borne in mind that multiple agents may have been ingested.</paragraph>
                        <paragraph>Flumazenil may be useful in situations when an overdose with a benzodiazepine is known or suspected. Prior to the administration of flumazenil, necessary measures should be instituted to secure airway, ventilation, and intravenous access. Flumazenil is intended as an adjunct to, not as a substitute for, proper management of benzodiazepine overdose. Patients treated with flumazenil should be monitored for re-sedation, respiratory depression, and other residual benzodiazepine effects for an appropriate period after treatment. The prescriber should be aware of a risk of seizure in association with flumazenil treatment, particularly in long-term benzodiazepine users and in cyclic antidepressant overdose. The complete flumazenil package insert should be consulted prior to use.</paragraph>
                     </text>
                     <effectiveTime value="20210412"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S11">
               <id root="ad5f59bc-bc4b-4d4f-994f-6f976e36d112"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <paragraph>Alprazolam Tablets, USP, contain alprazolam which is a triazolo analog of the 1,4 benzodiazepine class of central nervous system-active compounds.</paragraph>
                  <paragraph>The chemical name of alprazolam is 8-Chloro-1-methyl-6-phenyl-4H-s-triazolo [4,3-Î±] [1,4] benzodiazepine.</paragraph>
                  <paragraph>The structural formula is:</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM1"/>
                  </paragraph>
                  <paragraph>Alprazolam is a white crystalline powder, which is soluble in methanol or ethanol but which has no appreciable solubility in water at physiological pH.</paragraph>
                  <paragraph>Each Alprazolam tablet, USP, for oral administration, contains 0.25 mg, 0.5 mg, 1 mg, or 2 mg of alprazolam.</paragraph>
                  <paragraph>Alprazolam Tablets, USP, 2 mg, are multi-scored and may be divided as shown below:</paragraph>
                  <table width="100%" styleCode="Noautorules">
                     <col width="20%" align="center" valign="top"/>
                     <col width="20%" align="center" valign="top"/>
                     <col width="20%" align="center" valign="top"/>
                     <col width="20%" align="center" valign="top"/>
                     <col width="20%" align="center" valign="top"/>
                     <tbody>
                        <tr>
                           <td/>
                           <td>
                              <renderMultiMedia referencedObject="MM2"/>
                           </td>
                           <td>
                              <renderMultiMedia referencedObject="MM3"/>
                           </td>
                           <td>
                              <renderMultiMedia referencedObject="MM4"/>
                           </td>
                           <td/>
                        </tr>
                        <tr>
                           <td/>
                           <td>Complete 2 mg Tablet</td>
                           <td>Two 1 mg segments</td>
                           <td>Four 0.5 mg segments</td>
                           <td/>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>Inactive ingredients: Lactose monohydrate, microcrystalline cellulose, sodium starch glycolate, hydroxyl propyl cellulose, sodium lauryl sulfate and magnesium stearate. In addition, the 0.5 mg tablet contains FD&amp;C Yellow 6 lake and the 1 mg and 2 mg tablets contain FD&amp;C Blue 2 lake.</paragraph>
               </text>
               <effectiveTime value="20210412"/>
               <component>
                  <observationMedia ID="MM1">
                     <text>Chemical Structure</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="alprazolam-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM2">
                     <text>Figure</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="alprazolam-02.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM3">
                     <text>Figure</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="alprazolam-03.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM4">
                     <text>Figure</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="alprazolam-04.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="S12">
               <id root="360aea37-58a9-418b-84a4-b31bbdeee85d"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20210414"/>
               <component>
                  <section ID="S12.1">
                     <id root="f5f8dd1b-5506-4978-a5a9-9f8500920c1c"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <paragraph>Alprazolam is a 1,4 benzodiazepine. Alprazolam exerts its effect for the acute treatment of generalized anxiety disorder and panic disorder through binding to the benzodiazepine site of gamma-aminobutyric acid-A (GABA<sub>A</sub>) receptors in the brain and enhances GABA-mediated synaptic inhibition.</paragraph>
                     </text>
                     <effectiveTime value="20210412"/>
                  </section>
               </component>
               <component>
                  <section ID="S12.3">
                     <id root="aaf2a58d-a7f5-4a6a-9013-f4fa5cfd5645"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics</title>
                     <text>
                        <paragraph>Plasma levels of alprazolam increase proportionally to the dose over the range of 0.5 to 3.0 mg.</paragraph>
                     </text>
                     <effectiveTime value="20210414"/>
                     <component>
                        <section>
                           <id root="74cb69cc-5c40-4196-b4cf-31f2afeba45e"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Absorption</content>
                              </paragraph>
                              <paragraph>Following oral administration, peak plasma concentration of alprazolam (C<sub>max</sub>) occurs in 1 to 2 hours post dose.</paragraph>
                           </text>
                           <effectiveTime value="20210412"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="03e046d7-87b1-45ad-b7da-616395a20212"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Distribution</content>
                              </paragraph>
                              <paragraph>Alprazolam is 80% bound to human serum protein, and albumin accounts for the majority of the binding.</paragraph>
                           </text>
                           <effectiveTime value="20210412"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="186a2213-32a4-4c52-88d5-8cf31a503e5e"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Elimination</content>
                              </paragraph>
                              <paragraph>The mean plasma elimination half-life (T<sub>1/2</sub>) of alprazolam is approximately 11.2 hours (range: 6.3 to 26.9 hours) in healthy adults.</paragraph>
                           </text>
                           <effectiveTime value="20210412"/>
                           <component>
                              <section>
                                 <id root="941a9f2b-6832-43ab-a7b0-6e0aca3aebb6"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Metabolism</content>
                                    </paragraph>
                                    <paragraph>Alprazolam is extensively metabolized in humans, primarily by cytochrome P450 3A4 (CYP3A4), to 2 major active metabolites in the plasma: 4-hydroxyalprazolam and Î±-hydroxyalprazolam. The plasma circulation levels of the two active metabolites are less than 4% of the parent. The reported relative potencies in benzodiazepine receptor binding experiments and in animal models of induced seizure inhibition are 0.20 and 0.66, respectively, for 4-hydroxyalprazolam and Î±-hydroxyalprazolam. The low concentrations and low potencies of 4-hydroxyalprazolam and Î±-hydroxyalprazolam indicate that they unlikely contribute much to the effects of alprazolam. A benzophenone derived from alprazolam is also found in humans. Their half-lives appear to be similar to that of alprazolam.</paragraph>
                                 </text>
                                 <effectiveTime value="20210412"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="2ad71e82-9754-4eab-aaac-5b7533b6247f"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Excretion</content>
                                    </paragraph>
                                    <paragraph>Alprazolam and its metabolites are excreted primarily in the urine.</paragraph>
                                 </text>
                                 <effectiveTime value="20210412"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="d5c577e4-ea40-47ef-95ea-c7eba1e0ef4f"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Specific Populations</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20210412"/>
                           <component>
                              <section>
                                 <id root="1622c239-6ada-40df-a95d-5b09ced7bb7e"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Geriatric Patients</content>
                                    </paragraph>
                                    <paragraph>The mean T<sub>1/2</sub> of alprazolam was 16.3 hours (range: 9.0 to 26.9 hours) in healthy elderly subjects compared to 11.0 hours (range: 6.3 to 15.8 hours, n=16) in healthy younger adult subjects.</paragraph>
                                 </text>
                                 <effectiveTime value="20210412"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="ad1255ec-6ed2-4239-b086-104df0148b1d"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Obese Patients</content>
                                    </paragraph>
                                    <paragraph>The mean T<sub>1/2</sub> of alprazolam was 21.8 hours (range: 9.9 to 40.4 hours) in a group of obese subjects.</paragraph>
                                 </text>
                                 <effectiveTime value="20210412"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="e2daca38-fef0-45ee-b727-185bfbca1d1e"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Patients with Hepatic Impairment</content>
                                    </paragraph>
                                    <paragraph>The mean T<sub>1/2</sub> of alprazolam was 19.7 hours (range: 5.8 to 65.3 hours) in patients with alcoholic liver disease.</paragraph>
                                 </text>
                                 <effectiveTime value="20210412"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="cbd40ef6-46fe-4ee4-bb2f-92b3774c19d5"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Racial or Ethnic Groups</content>
                                    </paragraph>
                                    <paragraph>Maximal concentrations and T<sub>1/2</sub> of alprazolam are approximately 15% and 25% higher in Asians compared to Caucasians.</paragraph>
                                 </text>
                                 <effectiveTime value="20210412"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="445207a8-69e4-4d48-ae25-23f948a26612"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Smoking</content>
                                    </paragraph>
                                    <paragraph>Alprazolam concentrations may be reduced by up to 50% in smokers compared to non-smokers.</paragraph>
                                 </text>
                                 <effectiveTime value="20210412"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="e80880e0-14a6-46a5-b396-1739eeef9e2b"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Drug Interaction Studies</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20210414"/>
                           <component>
                              <section>
                                 <id root="81cf8921-6b29-4057-8ea6-dc7e6f54f16c"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">In Vivo Studies</content>
                                    </paragraph>
                                    <paragraph>Most of the interactions that have been documented with alprazolam are with drugs that modulate CYP3A4 activity.</paragraph>
                                    <paragraph>Compounds that are inhibitors or inducers of CYP3A would be expected to increase or decrease plasma alprazolam concentrations, respectively. Drug products that have been studied in vivo, along with their effect on increasing alprazolam AUC, are as follows: ketoconazole, 3.98 fold; itraconazole, 2.66 fold; nefazodone, 1.98 fold; fluvoxamine, 1.96 fold; and erythromycin, 1.61 fold <content styleCode="italics">[see <linkHtml href="#S4">Contraindications (4)</linkHtml>, <linkHtml href="#S5.5">Warnings and Precautions (5.5)</linkHtml>, <linkHtml href="#S7.2">Drug Interactions (7.2)</linkHtml>]</content>. Other studied drugs include:</paragraph>
                                 </text>
                                 <effectiveTime value="20210414"/>
                                 <component>
                                    <section>
                                       <id root="3d98a77d-ad61-42a5-8e15-5e12f68708d4"/>
                                       <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                       <text>
                                          <paragraph>
                                             <content styleCode="underline italics">Cimetidine:</content> Coadministration of cimetidine increased the maximum plasma concentration of alprazolam by 82%, decreased clearance by 42%, and increased T<sub>1/2</sub> by 16%.</paragraph>
                                       </text>
                                       <effectiveTime value="20210414"/>
                                    </section>
                                 </component>
                                 <component>
                                    <section>
                                       <id root="ef4be651-eb78-4bb8-9d42-cd99d345f340"/>
                                       <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                       <text>
                                          <paragraph>
                                             <content styleCode="underline italics">Fluoxetine:</content> Coadministration of fluoxetine with alprazolam increased the maximum plasma concentration of alprazolam by 46%, decreased clearance by 21%, increased T<sub>1/2</sub> by 17%, and decreased measured psychomotor performance.</paragraph>
                                       </text>
                                       <effectiveTime value="20210412"/>
                                    </section>
                                 </component>
                                 <component>
                                    <section>
                                       <id root="0dc46a94-b49e-46aa-a0a0-7cf4359457be"/>
                                       <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                       <text>
                                          <paragraph>
                                             <content styleCode="underline italics">Oral Contraceptives:</content> Coadministration of oral contraceptives increased the maximum plasma concentration of alprazolam by 18%, decreased clearance by 22%, and increased T<sub>1/2</sub> by 29%.</paragraph>
                                       </text>
                                       <effectiveTime value="20210414"/>
                                    </section>
                                 </component>
                                 <component>
                                    <section>
                                       <id root="63e05f4c-0076-49c9-90d0-e92bd03b111d"/>
                                       <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                       <text>
                                          <paragraph>
                                             <content styleCode="underline italics">Carbamazepine:</content> The oral clearance of alprazolam (given in a 0.8 mg single dose) was increased from 0.90Â±0.21 mL/min/kg to 2.13Â±0.54 mL/min/kg and the elimination T<sub>1/2</sub> was shortened (from 17.1Â±4.9 to 7.7Â±1.7 hour) following administration of 300 mg per day carbamazepine for 10 days <content styleCode="italics">[see <linkHtml href="#S7.2">Drug Interactions (7.2)</linkHtml>]</content>. However, the carbamazepine dose used in this study was fairly low compared to the recommended doses (1000-1200 mg per day); the effect at usual carbamazepine doses is unknown.</paragraph>
                                       </text>
                                       <effectiveTime value="20210412"/>
                                    </section>
                                 </component>
                                 <component>
                                    <section>
                                       <id root="2afa3ccd-6447-4ca6-b989-3905294eaabf"/>
                                       <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                       <text>
                                          <paragraph>
                                             <content styleCode="underline italics">Ritonavir:</content> Interactions involving HIV protease inhibitors (e.g., ritonavir) and alprazolam are complex and time dependent. Short-term low doses of ritonavir (4 doses of 200 mg) increased mean AUC of alprazolam by about 2.5-fold, and did not significantly affect C<sub>max</sub> of alprazolam. The elimination T<sub>1/2</sub> was prolonged (30 hours versus 13 hours). However, upon extended exposure to ritonavir (500 mg, twice daily for 10 days), CYP3A induction offset this inhibition. Alprazolam AUC and C<sub>max</sub> was reduced by 12% and 16%, respectively, in the presence of ritonavir. The elimination T<sub>1/2</sub> of alprazolam was not significantly changed <content styleCode="italics">[see <linkHtml href="#S5.5">Warnings and Precautions (5.5)</linkHtml>]</content>.</paragraph>
                                       </text>
                                       <effectiveTime value="20210412"/>
                                    </section>
                                 </component>
                                 <component>
                                    <section>
                                       <id root="bfcd2510-df6b-43ee-9a12-b65e10683142"/>
                                       <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                       <text>
                                          <paragraph>
                                             <content styleCode="underline italics">Sertraline:</content> A single dose of alprazolam 1 mg and steady state dose of sertraline (50 mg to 150 mg per day) did not reveal any clinically significant changes in the pharmacokinetics of alprazolam.</paragraph>
                                       </text>
                                       <effectiveTime value="20210412"/>
                                    </section>
                                 </component>
                                 <component>
                                    <section>
                                       <id root="d67c1851-4f40-46a1-8e58-8e9f94e6b176"/>
                                       <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                       <text>
                                          <paragraph>
                                             <content styleCode="underline italics">Imipramine and Desipramine:</content> The steady state plasma concentrations of imipramine and desipramine have been reported to be increased an average of 31% and 20%, respectively, by the concomitant administration of alprazolam tablets in doses up to 4 mg per day.</paragraph>
                                       </text>
                                       <effectiveTime value="20210412"/>
                                    </section>
                                 </component>
                                 <component>
                                    <section>
                                       <id root="5808481b-abb2-4d32-a76a-79bf3a4f78a8"/>
                                       <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                       <text>
                                          <paragraph>
                                             <content styleCode="underline italics">Warfarin:</content> Alprazolam did not affect the prothrombin or plasma warfarin levels in male volunteers administered sodium warfarin orally.</paragraph>
                                       </text>
                                       <effectiveTime value="20210412"/>
                                    </section>
                                 </component>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="087898f0-f29e-41b0-8a8e-8a0d01ee8250"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="underline italics">In Vitro Studies</content>
                                    </paragraph>
                                    <paragraph>Data from in vitro studies of alprazolam suggest a possible drug interaction of alprazolam with paroxetine. The ability of alprazolam to induce human hepatic enzyme systems has not yet been determined.</paragraph>
                                 </text>
                                 <effectiveTime value="20210412"/>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S13">
               <id root="063affe3-44c5-4955-b615-ca4154869c1c"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20210412"/>
               <component>
                  <section ID="S13.1">
                     <id root="b9927dbc-8880-48b6-8cf6-51932189adc1"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <effectiveTime value="20210412"/>
                     <component>
                        <section>
                           <id root="ae4b4546-95d3-4d3f-862e-12fbc039ebbd"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Carcinogenesis</content>
                              </paragraph>
                              <paragraph>No evidence of carcinogenic potential was observed in rats or mice administered alprazolam for 2-years at doses up to 30 and 10 mg/kg/day respectively. These doses are 29 times and 4.8 times the maximum recommended human dose of 10 mg/day based on mg/m<sup>2</sup> body surface area, respectively.</paragraph>
                           </text>
                           <effectiveTime value="20210412"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="4dcdf4c6-a77c-49bb-bb62-a7259591a85d"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Mutagenesis</content>
                              </paragraph>
                              <paragraph>Alprazolam was negative in the in vitro Ames bacterial reverse mutation assay and DNA Damage/Alkaline Elution Assay and in vivo rat micronucleus genetic toxicology assays.</paragraph>
                           </text>
                           <effectiveTime value="20210412"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="753f8f25-165b-4ab0-80e3-7fb8f3f8b1be"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Impairment of Fertility</content>
                              </paragraph>
                              <paragraph>Alprazolam produced no impairment of fertility in rats at doses up to 5 mg/kg per day, which is approximately 5 times the maximum recommended human dose of 10 mg per day based on mg/m<sup>2</sup> body surface area.</paragraph>
                           </text>
                           <effectiveTime value="20210412"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S13.2">
                     <id root="b088985c-1bf2-4aff-b56c-0ed1b9e0721b"/>
                     <code code="34091-9" codeSystem="2.16.840.1.113883.6.1" displayName="ANIMAL PHARMACOLOGY &amp; OR TOXICOLOGY SECTION"/>
                     <title>13.2 Animal Toxicology and/or Pharmacology</title>
                     <text>
                        <paragraph>When rats were treated with alprazolam at oral doses of 3 mg, 10 mg, and 30 mg/kg/day (3 to 29 times the maximum recommended human dose based on mg/m<sup>2</sup> body surface area) for 2 years, a tendency for a dose related increase in the number of cataracts was observed in females and a tendency for a dose related increase in corneal vascularization was observed in males. These lesions did not appear until after 11 months of treatment.</paragraph>
                     </text>
                     <effectiveTime value="20210412"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S14">
               <id root="d4bffc31-faa2-4e2b-ba2e-896d20fe50dd"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES</title>
               <effectiveTime value="20210412"/>
               <component>
                  <section ID="S14.1">
                     <id root="f4d9ca96-6448-4a39-971c-b77ed9349bfd"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.1 Generalized Anxiety Disorder</title>
                     <text>
                        <paragraph>Alprazolam tablets were compared to placebo in double-blind clinical studies (doses up to 4 mg per day) in patients with a diagnosis of anxiety or anxiety with associated depressive symptomatology. Alprazolam tablets were significantly better than placebo at each of the evaluation periods of these 4-week studies as judged by the following psychometric instruments: Physician's Global Impressions, Hamilton Anxiety Rating Scale, Target Symptoms, Patient's Global Impressions, and Self-Rating Symptom Scale.</paragraph>
                     </text>
                     <effectiveTime value="20210412"/>
                  </section>
               </component>
               <component>
                  <section ID="S14.2">
                     <id root="c652d7fc-5232-4526-a7bf-70455f9285e4"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.2 Panic Disorder</title>
                     <text>
                        <paragraph>The effectiveness of alprazolam tablets in the treatment of panic disorder was studied in 3 short-term, placebo-controlled studies (up to 10 weeks) in patients with diagnoses closely corresponding to DSM-III-R criteria for panic disorder.</paragraph>
                        <paragraph>The average dose of alprazolam tablets was 5 mg to 6 mg per day in 2 of the studies, and the doses of alprazolam tablets were fixed at 2 mg and 6 mg per day in the third study. In all 3 studies, alprazolam tablets were superior to placebo on a variable defined as "the number of patients with zero panic attacks" (range, 37% to 83% met this criterion), as well as on a global improvement score. In 2 of the 3 studies, alprazolam tablets were superior to placebo on a variable defined as "change from baseline on the number of panic attacks per week" (range, 3.3 to 5.2), and also on a phobia rating scale. A subgroup of patients who improved on alprazolam tablets during short-term treatment in 1 of these trials was continued on an open basis up to 8 months, without apparent loss of benefit.</paragraph>
                     </text>
                     <effectiveTime value="20210412"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S16">
               <id root="0274bcb9-3af8-4a1a-ad86-affcbed6ba92"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING</title>
               <text>
                  <paragraph>Product:    50090-5258</paragraph>
                  <paragraph>NDC:    50090-5258-1   30 TABLET in a BOTTLE</paragraph>
                  <paragraph>NDC:    50090-5258-2   60 TABLET in a BOTTLE</paragraph>
                  <paragraph>NDC:    50090-5258-3   100 TABLET in a BOTTLE</paragraph>
                  <paragraph>NDC:    50090-5258-0   90 TABLET in a BOTTLE</paragraph>
               </text>
               <effectiveTime value="20250402"/>
            </section>
         </component>
         <component>
            <section ID="S17">
               <id root="bb5b5ebd-38c2-4f1f-93a8-5e063e09bb47"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <text>
                  <paragraph>Advise the patient to read the FDA-approved patient labeling (Medication Guide).</paragraph>
               </text>
               <effectiveTime value="20210412"/>
               <component>
                  <section>
                     <id root="553b81c9-d80a-493d-9ce6-c29c318f29d1"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risks from Concomitant Use with Opioids</content>
                        </paragraph>
                        <paragraph>Advise both patients and caregivers about the risks of potentially fatal respiratory depression and sedation when alprazolam tablets are used with opioids and not to use such drugs concomitantly unless supervised by a healthcare provider. Advise patients not to drive or operate heavy machinery until the effects of concomitant use with the opioid have been determined <content styleCode="italics">[see <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>, <linkHtml href="#S7.1">Drug Interactions (7.1)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20210412"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="cd1aa31f-9d70-4962-836b-726511f1b896"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Abuse, Misuse, and Addiction</content>
                        </paragraph>
                        <paragraph>Inform patients that the use of alprazolam tablets, even at recommended dosages, exposes users to risks of abuse, misuse, and addiction, which can lead to overdose and death, especially when used in combination with other medications (e.g., opioid analgesics), alcohol, and/or illicit substances. Inform patients about the signs and symptoms of benzodiazepine abuse, misuse, and addiction; to seek medical help if they develop these signs and/or symptoms; and on the proper disposal of unused drug <content styleCode="italics">[see <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>, <linkHtml href="#S9.2">Drug Abuse and Dependence (9.2)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20210412"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="78648d13-580f-4dd6-82a1-a9c34ca7248e"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Withdrawal Reactions</content>
                        </paragraph>
                        <paragraph>Inform patients that the continued use of alprazolam tablets may lead to clinically significant physical dependence and that abrupt discontinuation or rapid dosage reduction of alprazolam tablets may precipitate acute withdrawal reactions, which can be life-threatening. Inform patients that in some cases, patients taking benzodiazepines have developed a protracted withdrawal syndrome with withdrawal symptoms lasting weeks to more than 12 months. Instruct patients that discontinuation or dosage reduction of alprazolam tablets may require a slow taper <content styleCode="italics">[see <linkHtml href="#S5.3">Warnings and Precautions (5.3)</linkHtml>, <linkHtml href="#S9.3">Drug Abuse and Dependence (9.3)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20210412"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="20e3817c-533b-4076-80df-3915f4e5c169"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Effects on Driving and Operating Machinery</content>
                        </paragraph>
                        <paragraph>Advise patients not to drive a motor vehicle or operate heavy machinery while taking alprazolam tablets due to its CNS depressant effects. Also advise patients to avoid use of alcohol or other CNS depressants while taking alprazolam tablets <content styleCode="italics">[see <linkHtml href="#S5.3">Warnings and Precautions (5.3)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20210412"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="a96e99c1-b0a8-4246-aa1c-0c4d7f58632c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Patients with Depression</content>
                        </paragraph>
                        <paragraph>Advise patients, their families, and caregivers to look for signs of suicidality or worsening depression, and to inform the patient's healthcare provider immediately <content styleCode="italics">[see <linkHtml href="#S5.6">Warnings and Precautions (5.6)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20210412"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="47632e3a-6350-4646-a1dc-5a51cf38b212"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Concomitant Medications</content>
                        </paragraph>
                        <paragraph>Advise patients to inform their healthcare provider of all medicines they take, including prescription and nonprescription medications, vitamins and herbal supplements <content styleCode="italics">[see <linkHtml href="#S7">Drug Interactions (7)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20210412"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="08b48738-b403-4dc1-81c0-626418980d89"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Pregnancy</content>
                        </paragraph>
                        <paragraph>Benzodiazepines cross the placenta and may produce respiratory depression and sedation in neonates. Advise mothers using alprazolam tablets to monitor neonates for signs of sedation, respiratory depression, withdrawal symptoms, and feeding problems. Instruct patients to inform their healthcare provider if they are pregnant or intend to become pregnant during treatment with alprazolam tablets <content styleCode="italics">[see <linkHtml href="#S5.4">Warnings and Precautions (5.4)</linkHtml>]</content>. Advise patients that there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to alprazolam tablets during pregnancy <content styleCode="italics">[see <linkHtml href="#S8.1">Use in Specific Populations (8.1)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20210412"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="a8368fbd-1758-4c7f-a58c-908fa1a89553"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Lactation</content>
                        </paragraph>
                        <paragraph>Advise women not to breastfeed during treatment with alprazolam tablets <content styleCode="italics">[see <linkHtml href="#S8.2">Use in Specific Populations (8.2)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20210412"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="736e822f-9c76-4e6a-b7db-b68c141fb8e1"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <text>
                  <paragraph>Manufactured By:<br/>Centaur Pharmaceuticals Pvt. Ltd.<br/>Pune â€“ 411057, INDIA.</paragraph>
                  <paragraph>Distributed by:<br/>Breckenridge Pharmaceutical, Inc.<br/>Berlin, CT 06037</paragraph>
                  <paragraph>211262</paragraph>
               </text>
               <effectiveTime value="20210412"/>
            </section>
         </component>
         <component>
            <section ID="MEDGUIDE">
               <id root="12095926-a525-4fff-940f-fed0879fd29f"/>
               <code code="42231-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL MEDGUIDE SECTION"/>
               <text>
                  <table>
                     <col width="3%" align="left" valign="top"/>
                     <col width="94%" align="left" valign="top"/>
                     <col width="3%" align="left" valign="top"/>
                     <tbody>
                        <tr>
                           <td styleCode="Lrule Rrule" colspan="3">Â </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule"/>
                           <td styleCode="Rrule Botrule Toprule" align="center">
                              <content styleCode="bold">MEDICATION GUIDE<br/>Alprazolam (al pra' zoe lam) <br/>Tablets, USP, C-IV</content>
                           </td>
                           <td styleCode="Rrule"/>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule" colspan="3">Â </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule" colspan="3">
                              <content styleCode="bold" ID="Important">What is the most important information I should know about alprazolam tablets?</content>
                              <list listType="unordered" styleCode="disc">
                                 <item>
                                    <content styleCode="bold">Alprazolam tablets are a benzodiazepine medicine. Taking benzodiazepines with opioid medicines, alcohol, or other central nervous system (CNS) depressants (including street drugs) can cause severe drowsiness, breathing problems (respiratory depression), coma and death.</content> Get emergency help right away if any of the following happens:<list listType="unordered" styleCode="circle">
                                       <item>shallow or slowed breathing</item>
                                       <item>breathing stops (which may lead to the heart stopping)</item>
                                       <item>excessive sleepiness (sedation)</item>
                                    </list>
                                 </item>
                              </list>Do not drive or operate heavy machinery until you know how taking alprazolam tablets with opioids affects you.<list listType="unordered" styleCode="disc">
                                 <item>
                                    <content styleCode="bold">Risk of abuse, misuse, and addiction.</content> There is a risk of abuse, misuse, and addiction with benzodiazepines, including alprazolam tablets, which can lead to overdose and serious side effects including coma and death.<list listType="unordered" styleCode="circle">
                                       <item>
                                          <content styleCode="bold">Serious side effects including coma and death have happened in people who have abused or misused benzodiazepines, including alprazolam tablets.</content> These serious side effects may also include delirium, paranoia, suicidal thoughts or actions, seizures, and difficulty breathing. <content styleCode="bold">Call your healthcare provider or go to the nearest hospital emergency room right away if you get any of these serious side effects.</content>
                                       </item>
                                       <item>
                                          <content styleCode="bold">You can develop an addiction even if you take alprazolam tablets as prescribed by your healthcare provider.</content>
                                       </item>
                                       <item>
                                          <content styleCode="bold">Take alprazolam tablets exactly as your healthcare provider prescribed.</content>
                                       </item>
                                       <item>Do not share your alprazolam tablets with other people.</item>
                                       <item>Keep alprazolam tablets in a safe place and away from children.</item>
                                    </list>
                                 </item>
                                 <item>
                                    <content styleCode="bold">Physical dependence and withdrawal reactions.</content> Alprazolam tablets can cause physical dependence and withdrawal reactions.<list listType="unordered" styleCode="circle">
                                       <item>
                                          <content styleCode="bold">Do not suddenly stop taking alprazolam tablets.</content> Stopping alprazolam tablets suddenly can cause serious and life-threatening side effects, including, unusual movements, responses, or expressions, seizures, sudden and severe mental or nervous system changes, depression, seeing or hearing things that others do not see or hear, an extreme increase in activity or talking, losing touch with reality, and suicidal thoughts or actions. <content styleCode="bold">Call your healthcare provider or go to the nearest hospital emergency room right away if you get any of these symptoms.</content>
                                       </item>
                                       <item>
                                          <content styleCode="bold">Some people who suddenly stop benzodiazepines, have symptoms that can last for several weeks to more than 12 months,</content> including, anxiety, trouble remembering, learning, or concentrating, depression, problems sleeping, feeling like insects are crawling under your skin, weakness, shaking, muscle twitching, burning or prickling feeling in your hands, arms, legs or feet, and ringing in your ears.</item>
                                       <item>Physical dependence is not the same as drug addiction. Your healthcare provider can tell you more about the differences between physical dependence and drug addiction.</item>
                                    </list>
                                 </item>
                                 <item>Do not take more alprazolam tablets than prescribed or take alprazolam tablets for longer than prescribed.</item>
                              </list>
                              <content styleCode="bold">What are alprazolam tablets?</content>
                              <list listType="unordered" styleCode="disc">
                                 <item>Alprazolam tablets are a prescription medicine used:<list listType="unordered" styleCode="circle">
                                       <item>to treat anxiety disorders</item>
                                       <item>for the short-term relief of the symptoms of anxiety</item>
                                       <item>to treat panic disorder with or without a fear of places and situations that might cause panic, helplessness, or embarrassment (agoraphobia)</item>
                                    </list>
                                 </item>
                                 <item>
                                    <content styleCode="bold">Alprazolam tablets are a federal controlled substance (C-IV) because they contain alprazolam that can be abused or lead to dependence.</content> Keep alprazolam tablets in a safe place to prevent misuse and abuse. Selling or giving away alprazolam tablets may harm others, and is against the law. Tell your healthcare provider if you have abused or been dependent on alcohol, prescription medicines or street drugs.</item>
                                 <item>It is not known if alprazolam tablets are safe and effective in children.</item>
                                 <item>Elderly patients are especially susceptible to dose related adverse effects when taking alprazolam tablets.</item>
                                 <item>It is not known if alprazolam tablets are safe and effective when used to treat anxiety disorder for longer than 4 months.</item>
                                 <item>It is not known if alprazolam tablets are safe and effective when used to treat panic disorder for longer than 10 weeks.</item>
                              </list>
                              <content styleCode="bold">Do not take alprazolam tablets if:</content>
                              <list listType="unordered" styleCode="disc">
                                 <item>you are allergic to alprazolam, other benzodiazepines, or any of the ingredients in alprazolam tablets. See the end of this Medication Guide for a complete list of ingredients in alprazolam tablets.</item>
                                 <item>you are taking antifungal medicines including ketoconazole and itraconazole.</item>
                              </list>
                              <content styleCode="bold">Before you take alprazolam tablets, tell your healthcare provider about all of your medical conditions, including if you:</content>
                              <list listType="unordered" styleCode="disc">
                                 <item>have or have had depression, mood problems, or suicidal thoughts or behavior</item>
                                 <item>have liver or kidney problems</item>
                                 <item>have lung disease or breathing problems</item>
                                 <item>are pregnant or plan to become pregnant. Alprazolam tablets may harm your unborn baby. You and your healthcare provider should decide if you should take alprazolam tablets while you are pregnant.</item>
                                 <item>are breastfeeding or plan to breastfeed. Alprazolam passes into your breast milk and may harm your baby. Talk to your healthcare provider about the best way to feed your baby if you take alprazolam tablets. You should not breastfeed while taking alprazolam tablets.</item>
                              </list>
                              <paragraph>
                                 <content styleCode="bold">Tell your healthcare provider about all the medicines you take,</content> including prescription and over-the-counter medicines, vitamins, and herbal supplements.</paragraph>
                              <paragraph>Taking alprazolam tablets with certain other medicines can cause side effects or affect how well alprazolam tablets or the other medicines work. Do not start or stop other medicines without talking to your healthcare provider.</paragraph>
                              <paragraph>
                                 <content styleCode="bold">How should I take alprazolam tablets?</content>
                              </paragraph>
                              <list listType="unordered" styleCode="disc">
                                 <item>See "<linkHtml href="#Important">What is the most important information I should know about alprazolam tablets?</linkHtml>"</item>
                                 <item>Take alprazolam tablets exactly as your healthcare provider tells you to take them. Your healthcare provider will tell you how much alprazolam tablets to take and when to take them.</item>
                                 <item>If you take too much alprazolam tablets, call your healthcare provider or go to the nearest hospital emergency room right away.</item>
                              </list>
                              <content styleCode="bold">What are the possible side effects of alprazolam tablets?</content>
                              <br/>
                              <content styleCode="bold">Alprazolam tablets may cause serious side effects, including:</content>
                              <list listType="unordered" styleCode="disc">
                                 <item>See "<linkHtml href="#Important">What is the most important information I should know about alprazolam tablets?</linkHtml>"</item>
                                 <item>
                                    <content styleCode="bold">Seizures.</content> Stopping alprazolam tablets can cause seizures and seizures that will not stop (status epilepticus).</item>
                                 <item>
                                    <content styleCode="bold">Mania.</content> Alprazolam tablets may cause an increase in activity and talking (hypomania and mania) in people who have depression.<list listType="unordered" styleCode="circle">
                                       <item>
                                          <content styleCode="bold">Alprazolam tablets can make you sleepy or dizzy and can slow your thinking and motor skills.</content> Do not drive, operate heavy machinery, or do other dangerous activities until you know how alprazolam tablets affect you.</item>
                                       <item>
                                          <content styleCode="bold">Do not drink alcohol or take other drugs that may make you sleepy or dizzy while taking alprazolam tablets without first talking to your healthcare provider.</content> When taken with alcohol or drugs that cause sleepiness or dizziness, alprazolam tablets may make your sleepiness or dizziness much worse.</item>
                                    </list>
                                 </item>
                              </list>
                              <content styleCode="bold">The most common side effects of alprazolam tablets include:</content>
                              <list listType="unordered" styleCode="disc">
                                 <item>problems with coordination</item>
                                 <item>hypotension</item>
                                 <item>trouble saying words clearly (dysarthria)</item>
                                 <item>changes in sex drive (libido)</item>
                              </list>These are not all the possible side effects of alprazolam tablets. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.<br/>
                              <content styleCode="bold">How should I store alprazolam tablets?</content>
                              <list listType="unordered" styleCode="disc">
                                 <item>Store alprazolam tablets at room temperature between 68Â°F to 77Â°F (20Â°C to 25Â°C)</item>
                                 <item>
                                    <content styleCode="bold">Keep alprazolam tablets and all medicines out of the reach of children.</content>
                                 </item>
                              </list>
                              <content styleCode="bold">General information about the safe and effective use of alprazolam tablets.</content>
                              <list listType="unordered" styleCode="disc">
                                 <item>Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide.</item>
                                 <item>Do not use alprazolam tablets for a condition for which it was not prescribed.</item>
                                 <item>Do not give alprazolam tablets to other people, even if they have the same symptoms that you have. It may harm them.</item>
                                 <item>You can ask your pharmacist or healthcare provider for information about alprazolam tablets that is written for health professionals.</item>
                              </list>
                              <content styleCode="bold">What are the ingredients in alprazolam tablets?</content>
                              <br/>
                              <content styleCode="bold">Active ingredient:</content> alprazolam<br/>
                              <content styleCode="bold">Inactive ingredients:</content> Lactose monohydrate, microcrystalline cellulose, sodium starch glycolate, hydroxyl propyl cellulose, sodium lauryl sulfate and magnesium stearate. In addition, the 0.5 mg tablet contains FD&amp;C Yellow 6 lake and the 1 mg and 2 mg tablets contain FD&amp;C Blue 2 lake.<br/>For more information, go to www.bpirx.com or call Breckenridge Pharmaceutical, Inc. 1-800-367-3395.<br/>This Medication Guide has been approved by the U.S. Food and Drug Administration.<br/>Manufactured By:<br/>Centaur Pharmaceuticals Pvt. Ltd.<br/>Pune â€“ 411057, INDIA.<br/>Distributed by:<br/>Breckenridge Pharmaceutical, Inc.<br/>Berlin, CT 06037<br/>Revised: 04/2021</td>
                        </tr>
                     </tbody>
                  </table>
               </text>
               <effectiveTime value="20210412"/>
            </section>
         </component>
         <component>
            <section>
               <id root="25de754e-b506-4608-a852-f682c31f46e6"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>ALPRAZOLAM TABLET</title>
               <text>
                  <renderMultiMedia referencedObject="lbl500905258"/>
               </text>
               <effectiveTime value="20250402"/>
               <component>
                  <observationMedia ID="lbl500905258">
                     <text>Label Image</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="lbl500905258.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>